(lp0
(dp1
S'contVal'
p2
NsS'drug2'
p3
S'http://bio2rdf.org/drugbank:DB00619'
p4
sS'drug1'
p5
S'http://bio2rdf.org/drugbank:DB00316'
p6
sS'objectUri'
p7
NsS'evidence'
p8
NsS'ddiPkMechanism'
p9
NsS'whoAnnotated'
p10
NsS'contraindication'
p11
NsS'researchStatementLabel'
p12
NsS'severity'
p13
NsS'label'
p14
NsS'effectConcept'
p15
NsS'source'
p16
S'DDI-Corpus-2011'
p17
sS'ddiPkEffect'
p18
NsS'evidenceType'
p19
NsS'homepage'
p20
NsS'pathway'
p21
NsS'ddiType'
p22
NsS'researchStatement'
p23
NsS'dateAnnotated'
p24
NsS'object'
p25
S'\xef\xbb\xbfACETAMINOPHEN'
p26
sS'evidenceSource'
p27
NsS'evidenceStatement'
p28
S'Systemic exposure to acetaminophen is expected to be increased when coadministered with Gleevec.| \r'
p29
sS'precipUri'
p30
NsS'certainty'
p31
NsS'uri'
p32
NsS'precip'
p33
NsS'numericVal'
p34
NsS'precaution'
p35
NsS'precipitant'
p36
S'Gleevec'
p37
sa(dp38
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p39
sg5
S'http://bio2rdf.org/drugbank:DB00459'
p40
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ACITRETIN'
p41
sg27
Nsg28
S'Ethanol:Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and ethanol.| \r'
p42
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p43
sa(dp44
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01016'
p45
sg5
S'http://bio2rdf.org/drugbank:DB00459'
p46
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ACITRETIN'
p47
sg27
Nsg28
S'Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.| \r'
p48
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Glibenclamide'
p49
sa(dp50
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p51
sg5
S'http://bio2rdf.org/drugbank:DB00459'
p52
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ACITRETIN'
p53
sg27
Nsg28
S'Phenytoin: If acitretin is given concurrently with phenytoin, the protein binding of phenytoin may be reduced.| \r'
p54
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p55
sa(dp56
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00437'
p57
sg5
S'http://bio2rdf.org/drugbank:DB00415'
p58
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ADENOSINE PHOSPHATE'
p59
sg27
Nsg28
S'Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.| \r'
p60
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALLOPURINOL'
p61
sa(dp62
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00201'
p63
sg5
S'http://bio2rdf.org/drugbank:DB00640'
p64
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ADENOSINE'
p65
sg27
Nsg28
S'The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.| \r'
p66
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CAFFEINE'
p67
sa(dp68
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00975'
p69
sg5
S'http://bio2rdf.org/drugbank:DB00640'
p70
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ADENOSINE'
p71
sg27
Nsg28
S'Adenosine effects are potentiated by dipyridamole.| Thus, smaller doses of adenosine may be effective in the presence of dipyridamole.| \r'
p72
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIPYRIDAMOLE'
p73
sa(dp74
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p75
sg5
S'http://bio2rdf.org/drugbank:DB00640'
p76
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ADENOSINE'
p77
sg27
Nsg28
S'The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.| \r'
p78
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p79
sa(dp80
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01159'
p81
sg5
S'http://bio2rdf.org/drugbank:DB00668'
p82
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Adrenaline'
p83
sg27
Nsg28
S'Caution should be exercised during the administration of adrenaline to patients anaesthetised with FLUOTHANE as arrhythmias may be precipitated.| \r'
p84
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Fluothane'
p85
sa(dp86
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01001'
p87
sg5
S'http://bio2rdf.org/drugbank:DB01001'
p88
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Albuterol'
p89
sg27
Nsg28
S'Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.| \r'
p90
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Albuterol'
p91
sa(dp92
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01238'
p93
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p94
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALCOHOL'
p95
sg27
Nsg28
S'As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY| \r'
p96
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Abilify'
p97
sa(dp98
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01213'
p99
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p100
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALCOHOL'
p101
sg27
Nsg28
S'Similarly, ethanol decreased the rate of elimination of Antizol (by approximately 50%) by the same mechanism.| \r'
p102
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Antizol'
p103
sa(dp104
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p105
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p106
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALCOHOL'
p107
sg27
Nsg28
S'Alcohol: Has a synergistic effect with aspirin in causing gastrointestinal bleeding.| \r'
p108
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p109
sa(dp110
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01205'
p111
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p112
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALCOHOL'
p113
sg27
Nsg28
S'Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, alcohol and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned.| \r'
p114
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Romazicon'
p115
sa(dp116
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00897'
p117
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p118
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALCOHOL'
p119
sg27
Nsg28
S'Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.| \r'
p120
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TRIAZOLAM'
p121
sa(dp122
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01156'
p123
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p124
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALCOHOL'
p125
sg27
Nsg28
S'The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS)| \r'
p126
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Wellbutrin'
p127
sa(dp128
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p129
sg5
S'http://bio2rdf.org/drugbank:DB00802'
p130
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Alfentanyl'
p131
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p132
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p133
sa(dp134
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p135
sg5
S'http://bio2rdf.org/drugbank:DB00802'
p136
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Alfentanyl'
p137
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p138
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p139
sa(dp140
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p141
sg5
S'http://bio2rdf.org/drugbank:DB01258'
p142
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALISKIREN'
p143
sg27
Nsg28
S'Furosemide When aliskiren was co-administered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.| \r'
p144
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FUROSEMIDE'
p145
sa(dp146
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p147
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p148
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALLOPURINOL'
p149
sg27
Nsg28
S'The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.| \r'
p150
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ADENOSINE PHOSPHATE'
p151
sa(dp152
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p153
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p154
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALLOPURINOL'
p155
sg27
Nsg28
S'The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.| \r'
p156
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPICILLIN'
p157
sa(dp158
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00993'
p159
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p160
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALLOPURINOL'
p161
sg27
Nsg28
S'Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.| \r'
p162
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AZATHIOPRINE'
p163
sa(dp164
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00672'
p165
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p166
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALLOPURINOL'
p167
sg27
Nsg28
S'The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.| \r'
p168
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CHLORPROPAMIDE'
p169
sa(dp170
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00266'
p171
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p172
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALLOPURINOL'
p173
sg27
Nsg28
S'The clinical basis of this drug interaction has not been established but should be noted when allopurinol is given to patients already on dicumarol therapy.| \r'
p174
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DICUMAROL'
p175
sa(dp176
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01033'
p177
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p178
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALLOPURINOL'
p179
sg27
Nsg28
S'In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.| Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.| \r'
p180
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MERCAPTOPURINE'
p181
sa(dp182
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p183
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p184
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALLOPURINOL'
p185
sg27
Nsg28
S'Allopurinol: The AUC of didanosine was increased about 4-fold when allopurinol at 300 mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and 18 mL/min).| \r'
p186
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Videx'
p187
sa(dp188
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p189
sg5
S'http://bio2rdf.org/drugbank:DB00918'
p190
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALMOTRIPTAN'
p191
sg27
Nsg28
S'Ketoconazole and Other Potent CYP3A4 Inhibitors Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.| \r'
p192
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p193
sa(dp194
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p195
sg5
S'http://bio2rdf.org/drugbank:DB00918'
p196
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALMOTRIPTAN'
p197
sg27
Nsg28
S'Verapamil Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.| \r'
p198
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p199
sa(dp200
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p201
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p202
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p203
sg27
Nsg28
S'The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.| \r'
p204
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p205
sa(dp206
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p207
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p208
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p209
sg27
Nsg28
S'The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.| \r'
p210
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'APREPITANT'
p211
sa(dp212
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p213
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p214
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p215
sg27
Nsg28
S'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| \r'
p216
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p217
sa(dp218
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p219
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p220
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p221
sg27
Nsg28
S'Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.| Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| \r'
p222
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p223
sa(dp224
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p225
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p226
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p227
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p228
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p229
sa(dp230
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p231
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p232
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p233
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p234
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p235
sa(dp236
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00467'
p237
sg5
S'http://bio2rdf.org/drugbank:DB06723'
p238
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALUMINUM HYDROXIDE'
p239
sg27
Nsg28
S'Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.| \r'
p240
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ENOXACIN'
p241
sa(dp242
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p243
sg5
S'http://bio2rdf.org/drugbank:DB00594'
p244
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'AMILORIDE'
p245
sg27
Nsg28
S'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.| \r'
p246
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOFETILIDE'
p247
sa(dp248
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00036'
p249
sg5
S'http://bio2rdf.org/drugbank:DB00513'
p250
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'AMINOCAPROIC ACID'
p251
sg27
Nsg28
S'Although the specific drug interaction was not studied in a clinical trial, there have been more than 50 episodes of concomitant use of antifibrinolytic therapies (i.e., tranexamic acid, aminocaproic acid) and NovoSeven.| \r'
p252
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NovoSeven'
p253
sa(dp254
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p255
sg5
S'http://bio2rdf.org/drugbank:DB01118'
p256
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'AMIODARONE'
p257
sg27
Nsg28
S'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| \r'
p258
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p259
sa(dp260
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p261
sg5
S'http://bio2rdf.org/drugbank:DB01118'
p262
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'AMIODARONE'
p263
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p264
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p265
sa(dp266
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p267
sg5
S'http://bio2rdf.org/drugbank:DB01118'
p268
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'AMIODARONE'
p269
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p270
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p271
sa(dp272
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p273
sg5
S'http://bio2rdf.org/drugbank:DB01118'
p274
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'AMIODARONE'
p275
sg27
Nsg28
S'Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| \r'
p276
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tikosyn'
p277
sa(dp278
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p279
sg5
S'http://bio2rdf.org/drugbank:DB00543'
p280
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'AMOXAPINE'
p281
sg27
Nsg28
S'Amoxapine may enhance the response to alcohol and the effects of barbiturates and other CNS depressants.| \r'
p282
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p283
sa(dp284
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00741'
p285
sg5
S'http://bio2rdf.org/drugbank:DB00681'
p286
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'AMPHOTERICIN B'
p287
sg27
Nsg28
S'In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.| \r'
p288
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HYDROCORTISONE'
p289
sa(dp290
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00437'
p291
sg5
S'http://bio2rdf.org/drugbank:DB00415'
p292
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'AMPICILLIN'
p293
sg27
Nsg28
S'Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.| \r'
p294
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALLOPURINOL'
p295
sa(dp296
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p297
sg5
S'http://bio2rdf.org/drugbank:DB00701'
p298
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'AMPRENAVIR'
p299
sg27
Nsg28
S'Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.| Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.| \r'
p300
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p301
sa(dp302
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p303
sg5
S'http://bio2rdf.org/drugbank:DB01242'
p304
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Anafranil'
p305
sg27
Nsg28
S'Because Anafranil is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g., warfarin, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.| \r'
p306
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p307
sa(dp308
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p309
sg5
S'http://bio2rdf.org/drugbank:DB00261'
p310
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ANAGRELIDE'
p311
sg27
Nsg28
S'Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin.| \r'
p312
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p313
sa(dp314
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB02527'
p315
sg5
S'http://bio2rdf.org/drugbank:DB00261'
p316
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ANAGRELIDE'
p317
sg27
Nsg28
S'Anagrelide is an inhibitor of cyclic AMP PDE III.| \r'
p318
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cyclic AMP'
p319
sa(dp320
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00675'
p321
sg5
S'http://bio2rdf.org/drugbank:DB01217'
p322
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ANASTROZOLE'
p323
sg27
Nsg28
S'Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.| \r'
p324
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TAMOXIFEN'
p325
sa(dp326
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p327
sg5
S'http://bio2rdf.org/drugbank:DB01213'
p328
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Antizol'
p329
sg27
Nsg28
S'Oral doses of Antizol (10-20 mg/kg), via alcohol dehydrogenase inhibition, significantly reduced the rate of elimination of ethanol (by approximately 40%) given to healthy volunteers in moderate doses.| \r'
p330
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p331
sa(dp332
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p333
sg5
S'http://bio2rdf.org/drugbank:DB01213'
p334
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Antizol'
p335
sg27
Nsg28
S'Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied| \r'
p336
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CARBAMAZEPINE'
p337
sa(dp338
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p339
sg5
S'http://bio2rdf.org/drugbank:DB01213'
p340
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Antizol'
p341
sg27
Nsg28
S'Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied| \r'
p342
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p343
sa(dp344
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00969'
p345
sg5
S'http://bio2rdf.org/drugbank:DB00714'
p346
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'APOMORPHINE'
p347
sg27
Nsg28
S'5HT3 Antagonists Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .| \r'
p348
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALOSETRON'
p349
sa(dp350
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00757'
p351
sg5
S'http://bio2rdf.org/drugbank:DB00714'
p352
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'APOMORPHINE'
p353
sg27
Nsg28
S'5HT3 Antagonists Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .| \r'
p354
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOLASETRON'
p355
sa(dp356
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p357
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p358
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'APREPITANT'
p359
sg27
Nsg28
S'therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.| \r'
p360
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CARBAMAZEPINE'
p361
sa(dp362
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01234'
p363
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p364
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'APREPITANT'
p365
sg27
Nsg28
S'Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.| \r'
p366
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DEXAMETHASONE'
p367
sa(dp368
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p369
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p370
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'APREPITANT'
p371
sg27
Nsg28
S'Aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.| \r'
p372
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHYLPREDNISOLONE'
p373
sa(dp374
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p375
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p376
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'APREPITANT'
p377
sg27
Nsg28
S'Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.| Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.| \r'
p378
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIDAZOLAM'
p379
sa(dp380
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p381
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p382
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'APREPITANT'
p383
sg27
Nsg28
S'Coadministration of Aprepitant with these drugs or other drugs that are known to be metabolized by CYP2C9, such as phenytoin, may result in lower plasma concentrations of these drugs.| \r'
p384
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p385
sa(dp386
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p387
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p388
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'APREPITANT'
p389
sg27
Nsg28
S'Rifampin: When a single 375-mg dose of Aprepitant was administered on Day9 of a 14-day regimen of 600 mg/day of rifampin, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold.| \r'
p390
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFAMPIN'
p391
sa(dp392
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p393
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p394
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'APREPITANT'
p395
sg27
Nsg28
S'Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| \r'
p396
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p397
sa(dp398
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p399
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p400
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'APREPITANT'
p401
sg27
Nsg28
S'Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.| \r'
p402
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOLBUTAMIDE'
p403
sa(dp404
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01361'
p405
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p406
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'APREPITANT'
p407
sg27
Nsg28
S'Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| \r'
p408
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TROLEANDOMYCIN'
p409
sa(dp410
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p411
sg5
S'http://bio2rdf.org/drugbank:DB01238'
p412
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ARIPIPRAZOLE'
p413
sg27
Nsg28
S'Quinidine: Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydroaripiprazole, by 35%.| \r'
p414
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'QUINIDINE'
p415
sa(dp416
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00482'
p417
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p418
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ASPIRIN'
p419
sg27
Nsg28
S'However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.| \r'
p420
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Celebrex'
p421
sa(dp422
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00573'
p423
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p424
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ASPIRIN'
p425
sg27
Nsg28
S'The coadministration of aspirin decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine.| \r'
p426
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Fenoprofen'
p427
sa(dp428
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00573'
p429
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p430
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ASPIRIN'
p431
sg27
Nsg28
S'Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.| \r'
p432
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nalfon'
p433
sa(dp434
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00627'
p435
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p436
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ASPIRIN'
p437
sg27
Nsg28
S'Aspirin: Concomitant aspirin may decrease the metabolic clearance of nicotinic acid.| \r'
p438
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nicotinic Acid'
p439
sa(dp440
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00585'
p441
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p442
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ASPIRIN'
p443
sg27
Nsg28
S'In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.| \r'
p444
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NIZATIDINE'
p445
sa(dp446
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00812'
p447
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p448
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ASPIRIN'
p449
sg27
Nsg28
S'Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.| \r'
p450
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYLBUTAZONE'
p451
sa(dp452
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p453
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p454
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ASPIRIN'
p455
sg27
Nsg28
S'Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.| \r'
p456
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROBENECID'
p457
sa(dp458
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00580'
p459
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p460
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ASPIRIN'
p461
sg27
Nsg28
S'Aspirin: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.| \r'
p462
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VALDECOXIB'
p463
sa(dp464
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00533'
p465
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p466
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ASPIRIN'
p467
sg27
Nsg28
S'Aspirin Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.| \r'
p468
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Vioxx'
p469
sa(dp470
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p471
sg5
S'http://bio2rdf.org/drugbank:DB00637'
p472
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ASTEMIZOLE'
p473
sg27
Nsg28
S'Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.| Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.| \r'
p474
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p475
sa(dp476
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01258'
p477
sg5
S'http://bio2rdf.org/drugbank:DB01076'
p478
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ATORVASTATIN'
p479
sg27
Nsg28
S'Co-administration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.| \r'
p480
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALISKIREN'
p481
sa(dp482
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p483
sg5
S'http://bio2rdf.org/drugbank:DB01076'
p484
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ATORVASTATIN'
p485
sg27
Nsg28
S'Cimetidine: Atorvastatin plasma concentrations and LDL-C reduction were not altered by coadministration of cimetidine.| \r'
p486
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIMETIDINE'
p487
sa(dp488
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p489
sg5
S'http://bio2rdf.org/drugbank:DB01076'
p490
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ATORVASTATIN'
p491
sg27
Nsg28
S'Digoxin: When multiple doses of atorvastatin and digoxin were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.| \r'
p492
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p493
sa(dp494
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p495
sg5
S'http://bio2rdf.org/drugbank:DB01076'
p496
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ATORVASTATIN'
p497
sg27
Nsg28
S'Erythromycin: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4.| \r'
p498
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERYTHROMYCIN'
p499
sa(dp500
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p501
sg5
S'http://bio2rdf.org/drugbank:DB00636'
p502
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Atromid-S'
p503
sg27
Nsg28
S'Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.| \r'
p504
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOLBUTAMIDE'
p505
sa(dp506
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00859'
p507
sg5
S'http://bio2rdf.org/drugbank:DB00995'
p508
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'AURANOFIN'
p509
sg27
Nsg28
S'Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.| \r'
p510
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cuprimine'
p511
sa(dp512
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00859'
p513
sg5
S'http://bio2rdf.org/drugbank:DB00995'
p514
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'AURANOFIN'
p515
sg27
Nsg28
S'Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.| \r'
p516
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PENICILLAMINE'
p517
sa(dp518
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00437'
p519
sg5
S'http://bio2rdf.org/drugbank:DB00993'
p520
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'AZATHIOPRINE'
p521
sg27
Nsg28
S'Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose.| Use with Allopurinol: The principal pathway for detoxification of azathioprine is inhibited by allopurinol.| \r'
p522
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALLOPURINOL'
p523
sa(dp524
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01435'
p525
sg5
S'http://bio2rdf.org/drugbank:DB00068'
p526
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Betaseron'
p527
sg27
Nsg28
S'Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.| \r'
p528
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ANTIPYRINE'
p529
sa(dp530
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01241'
p531
sg5
S'http://bio2rdf.org/drugbank:DB00307'
p532
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'BEXAROTENE'
p533
sg27
Nsg28
S'Concomitant administration of Targretin ? capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.| \r'
p534
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GEMFIBROZIL'
p535
sa(dp536
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p537
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p538
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Bextra'
p539
sg27
Nsg28
S'Lithium serum concentrations should be monitored closely when initiating or changing therapy with BEXTRA in patients receiving lithium.| \r'
p540
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p541
sa(dp542
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p543
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p544
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Bextra'
p545
sg27
Nsg28
S'Lithium serum concentrations should be monitored closely when initiating or changing therapy with BEXTRA in patients receiving lithium.| \r'
p546
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p547
sa(dp548
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB04665'
p549
sg5
S'http://bio2rdf.org/drugbank:DB01393'
p550
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Bezalip'
p551
sg27
Nsg28
S'When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.| \r'
p552
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'COUMARIN'
p553
sa(dp554
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00467'
p555
sg5
S'http://bio2rdf.org/drugbank:DB01294'
p556
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'BISMUTH SUBSALICYLATE'
p557
sg27
Nsg28
S'Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.| \r'
p558
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ENOXACIN'
p559
sa(dp560
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01076'
p561
sg5
S'http://bio2rdf.org/drugbank:DB00559'
p562
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'BOSENTAN ANHYDROUS'
p563
sg27
Nsg28
S'Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.| \r'
p564
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ATORVASTATIN'
p565
sa(dp566
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01016'
p567
sg5
S'http://bio2rdf.org/drugbank:DB00559'
p568
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'BOSENTAN ANHYDROUS'
p569
sg27
Nsg28
S'Co-administration of bosentan decreased the plasma concentrations of glyburide by approximately 40%.| \r'
p570
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GLYBURIDE'
p571
sa(dp572
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00227'
p573
sg5
S'http://bio2rdf.org/drugbank:DB00559'
p574
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'BOSENTAN ANHYDROUS'
p575
sg27
Nsg28
S'Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.| \r'
p576
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LOVASTATIN'
p577
sa(dp578
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00641'
p579
sg5
S'http://bio2rdf.org/drugbank:DB00559'
p580
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'BOSENTAN ANHYDROUS'
p581
sg27
Nsg28
S'Simvastatin and Other Statins: Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active ?-hydroxy acid metabolite, by approximately 50%.| \r'
p582
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SIMVASTATIN'
p583
sa(dp584
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01076'
p585
sg5
S'http://bio2rdf.org/drugbank:DB00559'
p586
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'BOSENTAN'
p587
sg27
Nsg28
S'Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.| \r'
p588
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ATORVASTATIN'
p589
sa(dp590
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01016'
p591
sg5
S'http://bio2rdf.org/drugbank:DB00559'
p592
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'BOSENTAN'
p593
sg27
Nsg28
S'Co-administration of bosentan decreased the plasma concentrations of glyburide by approximately 40%.| \r'
p594
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GLYBURIDE'
p595
sa(dp596
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00227'
p597
sg5
S'http://bio2rdf.org/drugbank:DB00559'
p598
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'BOSENTAN'
p599
sg27
Nsg28
S'Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.| \r'
p600
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LOVASTATIN'
p601
sa(dp602
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00641'
p603
sg5
S'http://bio2rdf.org/drugbank:DB00559'
p604
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'BOSENTAN'
p605
sg27
Nsg28
S'Simvastatin and Other Statins: Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active ?-hydroxy acid metabolite, by approximately 50%.| \r'
p606
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SIMVASTATIN'
p607
sa(dp608
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p609
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p610
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Brevibloc'
p611
sg27
Nsg28
S'Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.| \r'
p612
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p613
sa(dp614
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00988'
p615
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p616
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Brevibloc'
p617
sg27
Nsg28
S'Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.| \r'
p618
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOPAMINE'
p619
sa(dp620
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00668'
p621
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p622
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Brevibloc'
p623
sg27
Nsg28
S'Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.| \r'
p624
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EPINEPHRINE'
p625
sa(dp626
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p627
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p628
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Brevibloc'
p629
sg27
Nsg28
S'When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.| \r'
p630
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MORPHINE'
p631
sa(dp632
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00368'
p633
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p634
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Brevibloc'
p635
sg27
Nsg28
S'Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.| \r'
p636
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NOREPINEPHRINE'
p637
sa(dp638
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00202'
p639
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p640
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Brevibloc'
p641
sg27
Nsg28
S'Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.| \r'
p642
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUCCINYLCHOLINE'
p643
sa(dp644
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p645
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p646
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Brevibloc'
p647
sg27
Nsg28
S'Caution should be exercised when considering the use of BREVIBLOC and verapamil in patients with depressed myocardial function.| \r'
p648
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p649
sa(dp650
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00854'
p651
sg5
S'http://bio2rdf.org/drugbank:DB00921'
p652
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'BUPRENORPHINE'
p653
sg27
Nsg28
S'Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| \r'
p654
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Levo-Dromoran'
p655
sa(dp656
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00921'
p657
sg5
S'http://bio2rdf.org/drugbank:DB00921'
p658
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'BUPRENORPHINE'
p659
sg27
Nsg28
S'In many of these cases, buprenorphine was misused by self-injection of crushed SUBUTEX tablets.| \r'
p660
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Subutex'
p661
sa(dp662
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p663
sg5
S'http://bio2rdf.org/drugbank:DB00490'
p664
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'BUSPIRONE'
p665
sg27
Nsg28
S'In vitro, buspirone may displace less firmly bound drugs like digoxin.| \r'
p666
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p667
sa(dp668
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p669
sg5
S'http://bio2rdf.org/drugbank:DB01008'
p670
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'BUSULFAN'
p671
sg27
Nsg28
S'Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.| \r'
p672
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACETAMINOPHEN'
p673
sa(dp674
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01008'
p675
sg5
S'http://bio2rdf.org/drugbank:DB01008'
p676
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'BUSULFAN'
p677
sg27
Nsg28
S'Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.| \r'
p678
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Busulfex'
p679
sa(dp680
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p681
sg5
S'http://bio2rdf.org/drugbank:DB01008'
p682
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Busulfex'
p683
sg27
Nsg28
S'Since the pharmacokinetics of BUSULFEX were studied in patients treated with phenytoin, the clearance of BUSULFEX at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin.| \r'
p684
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p685
sa(dp686
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p687
sg5
S'http://bio2rdf.org/drugbank:DB00611'
p688
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'BUTORPHANOL'
p689
sg27
Nsg28
S'Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.| \r'
p690
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p691
sa(dp692
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00854'
p693
sg5
S'http://bio2rdf.org/drugbank:DB00611'
p694
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'BUTORPHANOL'
p695
sg27
Nsg28
S'Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| \r'
p696
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Levo-Dromoran'
p697
sa(dp698
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00201'
p699
sg5
S'http://bio2rdf.org/drugbank:DB00201'
p700
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CAFFEINE'
p701
sg27
Nsg28
S'Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.| \r'
p702
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CAFFEINE'
p703
sa(dp704
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p705
sg5
S'http://bio2rdf.org/drugbank:DB00201'
p706
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CAFFEINE'
p707
sg27
Nsg28
S'Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).| \r'
p708
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIMETIDINE'
p709
sa(dp710
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00363'
p711
sg5
S'http://bio2rdf.org/drugbank:DB00201'
p712
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CAFFEINE'
p713
sg27
Nsg28
S'Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.| \r'
p714
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLOZAPINE'
p715
sa(dp716
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00467'
p717
sg5
S'http://bio2rdf.org/drugbank:DB00201'
p718
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CAFFEINE'
p719
sg27
Nsg28
S'Caffeine-related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin.| Trough plasma enoxacin levels were also 20% higher when caffeine and enoxacin were administered concomitantly.| \r'
p720
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ENOXACIN'
p721
sa(dp722
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p723
sg5
S'http://bio2rdf.org/drugbank:DB00201'
p724
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CAFFEINE'
p725
sg27
Nsg28
S'Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).| \r'
p726
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p727
sa(dp728
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p729
sg5
S'http://bio2rdf.org/drugbank:DB00201'
p730
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CAFFEINE'
p731
sg27
Nsg28
S'Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).| \r'
p732
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p733
sa(dp734
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p735
sg5
S'http://bio2rdf.org/drugbank:DB00201'
p736
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CAFFEINE'
p737
sg27
Nsg28
S'Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).| \r'
p738
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p739
sa(dp740
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01412'
p741
sg5
S'http://bio2rdf.org/drugbank:DB00201'
p742
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CAFFEINE'
p743
sg27
Nsg28
S'Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.| \r'
p744
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOBROMINE'
p745
sa(dp746
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00136'
p747
sg5
S'http://bio2rdf.org/drugbank:DB00136'
p748
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CALCITRIOL'
p749
sg27
Nsg28
S'Since blood level of calcitriol/ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously.| \r'
p750
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Rocaltrol'
p751
sa(dp752
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00630'
p753
sg5
S'http://bio2rdf.org/drugbank:DB01373'
p754
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CALCIUM'
p755
sg27
Nsg28
S'Products containing calcium and other multivalent cations likely will interfere with absorption of alendronate.| \r'
p756
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALENDRONIC ACID'
p757
sa(dp758
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01196'
p759
sg5
S'http://bio2rdf.org/drugbank:DB01373'
p760
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CALCIUM'
p761
sg27
Nsg28
S'Milk, milk products, and calcium-rich foods or drugs may impair the absorption of EMCYT.| \r'
p762
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Emcyt'
p763
sa(dp764
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB04630'
p765
sg5
S'http://bio2rdf.org/drugbank:DB01197'
p766
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CAPTOPRIL'
p767
sg27
Nsg28
S'Agents Increasing Serum Potassium Since captopril decreases aldosterone production, elevation of serum potassium may occur.| \r'
p768
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALDOSTERONE'
p769
sa(dp770
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01238'
p771
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p772
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p773
sg27
Nsg28
S'Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.| When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled.| When carbamazepine is withdrawn from the combination therapy, aripiprazole dose should then be reduced.| \r'
p774
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ARIPIPRAZOLE'
p775
sa(dp776
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01068'
p777
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p778
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p779
sg27
Nsg28
S'Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.| \r'
p780
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLONAZEPAM'
p781
sa(dp782
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00254'
p783
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p784
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p785
sg27
Nsg28
S'Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.| \r'
p786
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOXYCYCLINE'
p787
sa(dp788
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p789
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p790
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p791
sg27
Nsg28
S'Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.| \r'
p792
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ESCITALOPRAM OXALATE'
p793
sa(dp794
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p795
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p796
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p797
sg27
Nsg28
S'Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.| \r'
p798
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ESCITALOPRAM'
p799
sa(dp800
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01215'
p801
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p802
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p803
sg27
Nsg28
S'While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.| \r'
p804
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ESTAZOLAM'
p805
sa(dp806
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00990'
p807
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p808
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p809
sg27
Nsg28
S'Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John?s wort) may significantly decrease exposure to exemestane.| \r'
p810
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EXEMESTANE'
p811
sa(dp812
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00949'
p813
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p814
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p815
sg27
Nsg28
S'The carbamazepine steady-state Cmin decreased 31% to 5?1 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered.| \r'
p816
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FELBAMATE'
p817
sa(dp818
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p819
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p820
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p821
sg27
Nsg28
S'Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.| \r'
p822
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p823
sa(dp824
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p825
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p826
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p827
sg27
Nsg28
S'Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.| \r'
p828
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p829
sa(dp830
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p831
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p832
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p833
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| \r'
p834
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p835
sa(dp836
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p837
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p838
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CARBAMAZEPINE'
p839
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| \r'
p840
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p841
sa(dp842
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p843
sg5
S'http://bio2rdf.org/drugbank:DB00482'
p844
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Celebrex'
p845
sg27
Nsg28
S'CELEBREX should be introduced at the lowest recommended dose in patients receiving fluconazole.| \r'
p846
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p847
sa(dp848
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p849
sg5
S'http://bio2rdf.org/drugbank:DB00482'
p850
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CELECOXIB'
p851
sg27
Nsg28
S'Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.| This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).| \r'
p852
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p853
sa(dp854
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p855
sg5
S'http://bio2rdf.org/drugbank:DB00482'
p856
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CELECOXIB'
p857
sg27
Nsg28
S'Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.| \r'
p858
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p859
sa(dp860
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p861
sg5
S'http://bio2rdf.org/drugbank:DB00482'
p862
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CELECOXIB'
p863
sg27
Nsg28
S'Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.| \r'
p864
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p865
sa(dp866
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00331'
p867
sg5
S'http://bio2rdf.org/drugbank:DB00567'
p868
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CEPHALEXIN ANHYDROUS'
p869
sg27
Nsg28
S'Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.| Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.| Metformin In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.| \r'
p870
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METFORMIN'
p871
sa(dp872
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p873
sg5
S'http://bio2rdf.org/drugbank:DB00567'
p874
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CEPHALEXIN ANHYDROUS'
p875
sg27
Nsg28
S'Probenecid As with other b-lactams, the renal excretion of cephalexin is inhibited by probenecid.| \r'
p876
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROBENECID'
p877
sa(dp878
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00331'
p879
sg5
S'http://bio2rdf.org/drugbank:DB00567'
p880
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CEPHALEXIN'
p881
sg27
Nsg28
S'Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.| Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.| Metformin In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.| \r'
p882
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METFORMIN'
p883
sa(dp884
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p885
sg5
S'http://bio2rdf.org/drugbank:DB00567'
p886
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CEPHALEXIN'
p887
sg27
Nsg28
S'Probenecid As with other b-lactams, the renal excretion of cephalexin is inhibited by probenecid.| \r'
p888
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROBENECID'
p889
sa(dp890
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p891
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p892
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CHLOROTRIANISENE'
p893
sg27
Nsg28
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p894
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p895
sa(dp896
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01200'
p897
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p898
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CHLOROTRIANISENE'
p899
sg27
Nsg28
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p900
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BROMOCRIPTINE'
p901
sa(dp902
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01373'
p903
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p904
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CHLOROTRIANISENE'
p905
sg27
Nsg28
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p906
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CALCIUM'
p907
sa(dp908
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p909
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p910
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CHLOROTRIANISENE'
p911
sg27
Nsg28
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p912
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSPORINE'
p913
sa(dp914
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01219'
p915
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p916
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CHLOROTRIANISENE'
p917
sg27
Nsg28
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p918
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DANTROLENE'
p919
sa(dp920
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00184'
p921
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p922
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CHLOROTRIANISENE'
p923
sg27
Nsg28
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p924
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NICOTINE'
p925
sa(dp926
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00052'
p927
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p928
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CHLOROTRIANISENE'
p929
sg27
Nsg28
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p930
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Somatropin'
p931
sa(dp932
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00675'
p933
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p934
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CHLOROTRIANISENE'
p935
sg27
Nsg28
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p936
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TAMOXIFEN'
p937
sa(dp938
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00321'
p939
sg5
S'http://bio2rdf.org/drugbank:DB00477'
p940
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CHLORPROMAZINE'
p941
sg27
Nsg28
S'The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.| \r'
p942
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMITRIPTYLINE'
p943
sa(dp944
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00988'
p945
sg5
S'http://bio2rdf.org/drugbank:DB00477'
p946
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CHLORPROMAZINE'
p947
sg27
Nsg28
S'Chlorpromazine - Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.| Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.| \r'
p948
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOPAMINE'
p949
sa(dp950
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00368'
p951
sg5
S'http://bio2rdf.org/drugbank:DB00477'
p952
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CHLORPROMAZINE'
p953
sg27
Nsg28
S'Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.| \r'
p954
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NOREPINEPHRINE'
p955
sa(dp956
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00437'
p957
sg5
S'http://bio2rdf.org/drugbank:DB00672'
p958
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CHLORPROPAMIDE'
p959
sg27
Nsg28
S'Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.| \r'
p960
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALLOPURINOL'
p961
sa(dp962
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p963
sg5
S'http://bio2rdf.org/drugbank:DB01239'
p964
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CHLORPROTHIXENE'
p965
sg27
Nsg28
S'Chlorprothixene may increase the plasma-level of concomitantly given lithium.| \r'
p966
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p967
sa(dp968
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p969
sg5
S'http://bio2rdf.org/drugbank:DB01239'
p970
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CHLORPROTHIXENE'
p971
sg27
Nsg28
S'Chlorprothixene may increase the plasma-level of concomitantly given lithium.| \r'
p972
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p973
sa(dp974
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p975
sg5
S'http://bio2rdf.org/drugbank:DB01410'
p976
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CICLESONIDE'
p977
sg27
Nsg28
S'In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.| \r'
p978
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p979
sa(dp980
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p981
sg5
S'http://bio2rdf.org/drugbank:DB01166'
p982
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CILOSTAZOL'
p983
sg27
Nsg28
S'Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of C.P.A..| \r'
p984
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DILTIAZEM'
p985
sa(dp986
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00802'
p987
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p988
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CIMETIDINE'
p989
sg27
Nsg28
S'Cimetidine reduces the clearance of ALFENTA.| \r'
p990
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alfenta'
p991
sa(dp992
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p993
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p994
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CIMETIDINE'
p995
sg27
Nsg28
S'H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.| The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.| \r'
p996
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p997
sa(dp998
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00363'
p999
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p1000
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CIMETIDINE'
p1001
sg27
Nsg28
S'Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.| \r'
p1002
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLOZAPINE'
p1003
sa(dp1004
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p1005
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p1006
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CIMETIDINE'
p1007
sg27
Nsg28
S'A study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels (58%) and AUC (53%) after a 1-week course of cimetidine 1200 mg/day and a single dose of diltiazem 60mg.| \r'
p1008
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DILTIAZEM'
p1009
sa(dp1010
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p1011
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p1012
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CIMETIDINE'
p1013
sg27
Nsg28
S'Cimetidine at doses of 100 mg BID (OTC dose) resulted in a 13% increase in dofetilide plasma levels (500 mcg single dose).| \r'
p1014
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOFETILIDE'
p1015
sa(dp1016
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00445'
p1017
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p1018
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CIMETIDINE'
p1019
sg27
Nsg28
S'Cimetidine treatment should be stopped during treatment with ELLENCE.| \r'
p1020
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ellence'
p1021
sa(dp1022
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00445'
p1023
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p1024
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CIMETIDINE'
p1025
sg27
Nsg28
S'Cimetidine increased the AUC of epirubicin by 50%.| \r'
p1026
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EPIRUBICIN'
p1027
sa(dp1028
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00996'
p1029
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p1030
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CIMETIDINE'
p1031
sg27
Nsg28
S'Cimetidine: In the presence of cimetidine at 300 mg QID (N=12) the mean apparent oral clearance of gabapentin fell by 14% and creatinine clearance fell by 10%.| Thus cimetidine appeared to alter the renal excretion of both gabapentin and creatinine, an endogenous marker of renal function.| \r'
p1032
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GABAPENTIN'
p1033
sa(dp1034
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p1035
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p1036
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CIMETIDINE'
p1037
sg27
Nsg28
S'Cimetidine at 400 mg BID (the usual prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide plasma levels by 58%.| \r'
p1038
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tikosyn'
p1039
sa(dp1040
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00321'
p1041
sg5
S'http://bio2rdf.org/drugbank:DB01012'
p1042
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CINACALCET'
p1043
sg27
Nsg28
S'Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.| \r'
p1044
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMITRIPTYLINE'
p1045
sa(dp1046
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00201'
p1047
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p1048
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CIPROFLOXACIN'
p1049
sg27
Nsg28
S'Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine.| \r'
p1050
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CAFFEINE'
p1051
sa(dp1052
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p1053
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p1054
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CIPROFLOXACIN'
p1055
sg27
Nsg28
S'Some quinolones, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.| \r'
p1056
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSPORINE'
p1057
sa(dp1058
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p1059
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p1060
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CIPROFLOXACIN'
p1061
sg27
Nsg28
S'In a single subject given one dose of ciprofloxacin 2 hours after a dose of didanosine-placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed.| The AUC of ciprofloxacin was decreased an average of 15-fold in 12 healthy subjects given ciprofloxacin and didanosine-placebo tablets concurrently.| \r'
p1062
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIDANOSINE'
p1063
sa(dp1064
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01592'
p1065
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p1066
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CIPROFLOXACIN'
p1067
sg27
Nsg28
S'Multivalent Cation-Containing Products Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| \r'
p1068
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'IRON'
p1069
sa(dp1070
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01378'
p1071
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p1072
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CIPROFLOXACIN'
p1073
sg27
Nsg28
S'Multivalent Cation-Containing Products Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| \r'
p1074
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MAGNESIUM CATION'
p1075
sa(dp1076
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01378'
p1077
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p1078
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CIPROFLOXACIN'
p1079
sg27
Nsg28
S'Multivalent Cation-Containing Products Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| \r'
p1080
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MAGNESIUM'
p1081
sa(dp1082
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p1083
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p1084
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CIPROFLOXACIN'
p1085
sg27
Nsg28
S'Theophylline As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.| \r'
p1086
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p1087
sa(dp1088
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p1089
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p1090
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CIPROFLOXACIN'
p1091
sg27
Nsg28
S'Multivalent Cation-Containing Products Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| \r'
p1092
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Videx'
p1093
sa(dp1094
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01593'
p1095
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p1096
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CIPROFLOXACIN'
p1097
sg27
Nsg28
S'Multivalent Cation-Containing Products Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| \r'
p1098
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZINC'
p1099
sa(dp1100
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1101
sg5
S'http://bio2rdf.org/drugbank:DB00604'
p1102
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Cisapride'
p1103
sg27
Nsg28
S'A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.| Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.| \r'
p1104
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p1105
sa(dp1106
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01060'
p1107
sg5
S'http://bio2rdf.org/drugbank:DB01211'
p1108
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CLARITHROMYCIN'
p1109
sg27
Nsg28
S'Combination Therapy with Clarithromycin Co-administration of esomeprazole, clarithromycin, and amoxicillin has resulted in increases in the plasma levels of esomeprazole and 14-hydroxyclarithromycin.| \r'
p1110
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMOXICILLIN ANHYDROUS'
p1111
sa(dp1112
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01060'
p1113
sg5
S'http://bio2rdf.org/drugbank:DB01211'
p1114
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CLARITHROMYCIN'
p1115
sg27
Nsg28
S'Combination Therapy with Clarithromycin Co-administration of esomeprazole, clarithromycin, and amoxicillin has resulted in increases in the plasma levels of esomeprazole and 14-hydroxyclarithromycin.| \r'
p1116
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMOXICILLIN'
p1117
sa(dp1118
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p1119
sg5
S'http://bio2rdf.org/drugbank:DB01211'
p1120
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CLARITHROMYCIN'
p1121
sg27
Nsg28
S'Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| \r'
p1122
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p1123
sa(dp1124
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p1125
sg5
S'http://bio2rdf.org/drugbank:DB01211'
p1126
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CLARITHROMYCIN'
p1127
sg27
Nsg28
S'Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.| \r'
p1128
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p1129
sa(dp1130
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00238'
p1131
sg5
S'http://bio2rdf.org/drugbank:DB01211'
p1132
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CLARITHROMYCIN'
p1133
sg27
Nsg28
S'Clarithromycin exposure was significantly decreased by nevirapine;| \r'
p1134
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NEVIRAPINE'
p1135
sa(dp1136
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01100'
p1137
sg5
S'http://bio2rdf.org/drugbank:DB01211'
p1138
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CLARITHROMYCIN'
p1139
sg27
Nsg28
S'Concomitant administration of clarithromycin with pimozide is contraindicated.| \r'
p1140
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PIMOZIDE'
p1141
sa(dp1142
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p1143
sg5
S'http://bio2rdf.org/drugbank:DB01242'
p1144
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CLOMIPRAMINE'
p1145
sg27
Nsg28
S'Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.| \r'
p1146
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p1147
sa(dp1148
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00794'
p1149
sg5
S'http://bio2rdf.org/drugbank:DB01242'
p1150
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CLOMIPRAMINE'
p1151
sg27
Nsg28
S'Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.| \r'
p1152
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PRIMIDONE'
p1153
sa(dp1154
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00782'
p1155
sg5
S'http://bio2rdf.org/drugbank:DB01068'
p1156
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CLONAZEPAM'
p1157
sg27
Nsg28
S'In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.| \r'
p1158
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROPANTHELINE'
p1159
sa(dp1160
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00572'
p1161
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p1162
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CLOZAPINE'
p1163
sg27
Nsg28
S'Clozapine may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine-type drugs.| \r'
p1164
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Atropine'
p1165
sa(dp1166
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p1167
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p1168
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CLOZAPINE'
p1169
sg27
Nsg28
S'Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.| Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.| \r'
p1170
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CARBAMAZEPINE'
p1171
sa(dp1172
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01228'
p1173
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p1174
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CLOZAPINE'
p1175
sg27
Nsg28
S'Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.| \r'
p1176
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Encainide'
p1177
sa(dp1178
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p1179
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p1180
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CLOZAPINE'
p1181
sg27
Nsg28
S'However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.| \r'
p1182
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PAROXETINE'
p1183
sa(dp1184
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p1185
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p1186
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CLOZAPINE'
p1187
sg27
Nsg28
S'Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.| \r'
p1188
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'QUINIDINE'
p1189
sa(dp1190
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01104'
p1191
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p1192
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CLOZAPINE'
p1193
sg27
Nsg28
S'However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.| \r'
p1194
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SERTRALINE'
p1195
sa(dp1196
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01452'
p1197
sg5
S'http://bio2rdf.org/drugbank:DB00907'
p1198
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'COCAINE'
p1199
sg27
Nsg28
S'Cocaine sometimes proves to be fatal when used in combination with heroin.| \r'
p1200
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIACETYLMORPHINE'
p1201
sa(dp1202
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00115'
p1203
sg5
S'http://bio2rdf.org/drugbank:DB01394'
p1204
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'COLCHICINE'
p1205
sg27
Nsg28
S'Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.| \r'
p1206
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Vitamin B12'
p1207
sa(dp1208
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p1209
sg5
S'http://bio2rdf.org/drugbank:DB00811'
p1210
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Copegus'
p1211
sg27
Nsg28
S'Nucleoside Analogues Didanosine Co-administration of COPEGUS and didanosine is not recommended.| \r'
p1212
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIDANOSINE'
p1213
sa(dp1214
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01072'
p1215
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p1216
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Crixivan'
p1217
sg27
Nsg28
S'Combinations of these drugs have not been studied and coadministration of CRIXIVAN and atazanavir is not recommended.| \r'
p1218
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ATAZANAVIR'
p1219
sa(dp1220
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00705'
p1221
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p1222
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Crixivan'
p1223
sg27
Nsg28
S'Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered when taking delavirdine 400 mg three times a day.| \r'
p1224
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DELAVIRDINE'
p1225
sa(dp1226
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00437'
p1227
sg5
S'http://bio2rdf.org/drugbank:DB00531'
p1228
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Cyclophosphamide'
p1229
sg27
Nsg28
S'Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.| \r'
p1230
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALLOPURINOL'
p1231
sa(dp1232
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p1233
sg5
S'http://bio2rdf.org/drugbank:DB00531'
p1234
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Cyclophosphamide'
p1235
sg27
Nsg28
S'The rate of metabolism and the leukopenic activity of cyclophosphamide reportedly are increased by chronic administration of high doses of phenobarbital.| \r'
p1236
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p1237
sa(dp1238
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00773'
p1239
sg5
S'http://bio2rdf.org/drugbank:DB00091'
p1240
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Cyclosporin A'
p1241
sg27
Nsg28
S'High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.| \r'
p1242
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ETOPOSIDE'
p1243
sa(dp1244
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p1245
sg5
S'http://bio2rdf.org/drugbank:DB00091'
p1246
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CYCLOSPORINE'
p1247
sg27
Nsg28
S'Therefore, cyclosporine serum levels should be monitored and appropriate cyclosporine dosage adjustments made when these drugs are used concomitantly.| \r'
p1248
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSPORINE'
p1249
sa(dp1250
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p1251
sg5
S'http://bio2rdf.org/drugbank:DB00091'
p1252
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CYCLOSPORINE'
p1253
sg27
Nsg28
S'If these agents are to be administered concurrently, cyclosporine concentrations should be monitored, especially when diltiazem therapy is initiated, adjusted, or discontinued.| \r'
p1254
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DILTIAZEM'
p1255
sa(dp1256
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01059'
p1257
sg5
S'http://bio2rdf.org/drugbank:DB00091'
p1258
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CYCLOSPORINE'
p1259
sg27
Nsg28
S'Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with norfloxacin.| \r'
p1260
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NORFLOXACIN'
p1261
sa(dp1262
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00738'
p1263
sg5
S'http://bio2rdf.org/drugbank:DB00091'
p1264
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CYCLOSPORINE'
p1265
sg27
Nsg28
S'Other nephrotoxic medications: agents such as aminoglycosides, cyclosporine, and pentamidine may enhance the potential for drug-induced renal toxicity, and should be used concomitantly only with great caution.| \r'
p1266
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PENTAMIDINE'
p1267
sa(dp1268
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p1269
sg5
S'http://bio2rdf.org/drugbank:DB00091'
p1270
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CYCLOSPORINE'
p1271
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p1272
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p1273
sa(dp1274
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p1275
sg5
S'http://bio2rdf.org/drugbank:DB00091'
p1276
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CYCLOSPORINE'
p1277
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p1278
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p1279
sa(dp1280
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01234'
p1281
sg5
S'http://bio2rdf.org/drugbank:DB00357'
p1282
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Cytadren'
p1283
sg27
Nsg28
S'Cytadren accelerates the metabolism of dexamethasone;| \r'
p1284
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DEXAMETHASONE'
p1285
sa(dp1286
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01099'
p1287
sg5
S'http://bio2rdf.org/drugbank:DB00987'
p1288
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Cytosine arabinoside'
p1289
sg27
Nsg28
S'Cytosine arabinoside, a cytostatic agent, has been reported to inactivate the antifungal activity of flucytosine by competitive inhibition.| \r'
p1290
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCYTOSINE'
p1291
sa(dp1292
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01151'
p1293
sg5
S'http://bio2rdf.org/drugbank:DB01576'
p1294
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'd-amphetamine'
p1295
sg27
Nsg28
S'd-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;| \r'
p1296
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DESIPRAMINE'
p1297
sa(dp1298
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00344'
p1299
sg5
S'http://bio2rdf.org/drugbank:DB01576'
p1300
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'd-amphetamine'
p1301
sg27
Nsg28
S'd-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;| \r'
p1302
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROTRIPTYLINE'
p1303
sa(dp1304
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00227'
p1305
sg5
S'http://bio2rdf.org/drugbank:DB01406'
p1306
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DANAZOL'
p1307
sg27
Nsg28
S'Danazol: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of danazol particularly with higher doses of lovastatin (see WARNINGS, Myopathy/Rhabdomyolysis).| \r'
p1308
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LOVASTATIN'
p1309
sa(dp1310
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01339'
p1311
sg5
S'http://bio2rdf.org/drugbank:DB01219'
p1312
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DANTROLENE'
p1313
sg27
Nsg28
S'Administration of dantrolene may potentiate vecuronium-induced neuromuscular block.| \r'
p1314
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VECURONIUM'
p1315
sa(dp1316
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00205'
p1317
sg5
S'http://bio2rdf.org/drugbank:DB00250'
p1318
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DAPSONE'
p1319
sg27
Nsg28
S'With oral dapsone treatment, folic acid antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions| \r'
p1320
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PYRIMETHAMINE'
p1321
sa(dp1322
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p1323
sg5
S'http://bio2rdf.org/drugbank:DB00250'
p1324
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DAPSONE'
p1325
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p1326
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p1327
sa(dp1328
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p1329
sg5
S'http://bio2rdf.org/drugbank:DB00250'
p1330
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DAPSONE'
p1331
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p1332
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p1333
sa(dp1334
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p1335
sg5
S'http://bio2rdf.org/drugbank:DB00705'
p1336
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DELAVIRDINE'
p1337
sg27
Nsg28
S'Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.| To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.| \r'
p1338
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Videx'
p1339
sa(dp1340
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00518'
p1341
sg5
S'http://bio2rdf.org/drugbank:DB01234'
p1342
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DEXAMETHASONE'
p1343
sg27
Nsg28
S'Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.| \r'
p1344
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALBENDAZOLE'
p1345
sa(dp1346
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p1347
sg5
S'http://bio2rdf.org/drugbank:DB01234'
p1348
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DEXAMETHASONE'
p1349
sg27
Nsg28
S'The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.| \r'
p1350
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'APREPITANT'
p1351
sa(dp1352
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p1353
sg5
S'http://bio2rdf.org/drugbank:DB01234'
p1354
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DEXAMETHASONE'
p1355
sg27
Nsg28
S'Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| \r'
p1356
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p1357
sa(dp1358
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p1359
sg5
S'http://bio2rdf.org/drugbank:DB01234'
p1360
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DEXAMETHASONE'
p1361
sg27
Nsg28
S'Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| \r'
p1362
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p1363
sa(dp1364
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p1365
sg5
S'http://bio2rdf.org/drugbank:DB00405'
p1366
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DEXBROMPHENIRAMINE'
p1367
sg27
Nsg28
S'Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).| \r'
p1368
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p1369
sa(dp1370
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p1371
sg5
S'http://bio2rdf.org/drugbank:DB01452'
p1372
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIACETYLMORPHINE'
p1373
sg27
Nsg28
S'Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.| \r'
p1374
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p1375
sa(dp1376
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p1377
sg5
S'http://bio2rdf.org/drugbank:DB01452'
p1378
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIACETYLMORPHINE'
p1379
sg27
Nsg28
S'Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.| \r'
p1380
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIAZEPAM'
p1381
sa(dp1382
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p1383
sg5
S'http://bio2rdf.org/drugbank:DB00829'
p1384
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIAZEPAM'
p1385
sg27
Nsg28
S'Accordingly, diazepam and fluvoxamine should not ordinarily be co-administered.| \r'
p1386
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p1387
sa(dp1388
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00580'
p1389
sg5
S'http://bio2rdf.org/drugbank:DB00829'
p1390
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIAZEPAM'
p1391
sg27
Nsg28
S'Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.| \r'
p1392
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VALDECOXIB'
p1393
sa(dp1394
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01275'
p1395
sg5
S'http://bio2rdf.org/drugbank:DB01119'
p1396
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIAZOXIDE'
p1397
sg27
Nsg28
S'Profound hypotensive episodes may occur when diazoxide infection and hydralazine are used concomitantly.| \r'
p1398
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HYDRALAZINE'
p1399
sa(dp1400
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p1401
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p1402
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DICLOFENAC'
p1403
sg27
Nsg28
S'Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.| \r'
p1404
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p1405
sa(dp1406
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p1407
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p1408
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DICLOFENAC'
p1409
sg27
Nsg28
S'Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.| \r'
p1410
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSPORINE'
p1411
sa(dp1412
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p1413
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p1414
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DICLOFENAC'
p1415
sg27
Nsg28
S'Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine?s nephrotoxicity.| Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.| \r'
p1416
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p1417
sa(dp1418
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p1419
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p1420
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DICLOFENAC'
p1421
sg27
Nsg28
S'In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.| \r'
p1422
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p1423
sa(dp1424
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p1425
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p1426
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DICLOFENAC'
p1427
sg27
Nsg28
S'In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.| \r'
p1428
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p1429
sa(dp1430
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p1431
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p1432
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DICLOFENAC'
p1433
sg27
Nsg28
S'Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine?s nephrotoxicity.| Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.| \r'
p1434
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHOTREXATE'
p1435
sa(dp1436
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00860'
p1437
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p1438
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DICLOFENAC'
p1439
sg27
Nsg28
S'Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.| \r'
p1440
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PREDNISOLONE'
p1441
sa(dp1442
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00936'
p1443
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p1444
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DICLOFENAC'
p1445
sg27
Nsg28
S'Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.| \r'
p1446
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SALICYLIC ACID'
p1447
sa(dp1448
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p1449
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p1450
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DICLOFENAC'
p1451
sg27
Nsg28
S'Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.| \r'
p1452
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOLBUTAMIDE'
p1453
sa(dp1454
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p1455
sg5
S'http://bio2rdf.org/drugbank:DB00804'
p1456
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DICYCLOMINE'
p1457
sg27
Nsg28
S'Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.| \r'
p1458
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p1459
sa(dp1460
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p1461
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p1462
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIFLUNISAL'
p1463
sg27
Nsg28
S'Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.| Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.| Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.| \r'
p1464
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACETAMINOPHEN'
p1465
sa(dp1466
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p1467
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p1468
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIFLUNISAL'
p1469
sg27
Nsg28
S'Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.| \r'
p1470
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p1471
sa(dp1472
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p1473
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p1474
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIFLUNISAL'
p1475
sg27
Nsg28
S'Diflunisal decreased the hyperuricemic effect of furosemide.| \r'
p1476
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FUROSEMIDE'
p1477
sa(dp1478
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00999'
p1479
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p1480
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIFLUNISAL'
p1481
sg27
Nsg28
S'Diflunisal decreased the hyperuricemic effect of hydrochlorothiazide.| Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.| \r'
p1482
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HYDROCHLOROTHIAZIDE'
p1483
sa(dp1484
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00328'
p1485
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p1486
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIFLUNISAL'
p1487
sg27
Nsg28
S'Nonsteroidal Anti-Inflammatory Drugs The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.| \r'
p1488
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDOMETHACIN'
p1489
sa(dp1490
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p1491
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p1492
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIFLUNISAL'
p1493
sg27
Nsg28
S'Methotrexate: Caution should be used if diflunisal is administered concomitantly with methotrexate.| \r'
p1494
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHOTREXATE'
p1495
sa(dp1496
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00788'
p1497
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p1498
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIFLUNISAL'
p1499
sg27
Nsg28
S'Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.| \r'
p1500
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NAPROXEN'
p1501
sa(dp1502
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00640'
p1503
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1504
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIGOXIN'
p1505
sg27
Nsg28
S'Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.| \r'
p1506
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Adenocard'
p1507
sa(dp1508
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00187'
p1509
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1510
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIGOXIN'
p1511
sg27
Nsg28
S'When digoxin and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.| \r'
p1512
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Brevibloc'
p1513
sa(dp1514
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00872'
p1515
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1516
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIGOXIN'
p1517
sg27
Nsg28
S'Digoxin Coadministration of digoxin, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.| \r'
p1518
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CONIVAPTAN'
p1519
sa(dp1520
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00531'
p1521
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1522
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIGOXIN'
p1523
sg27
Nsg28
S'Reversible decreases in steady-state plasma digoxin concentrations and renal glycoside excretion were observed in patients receiving beta-acetyl digoxin and chemotherapy regimens containing cyclophosphamide, vincristine, and prednisone with or without cytarabine or procarbazine.| \r'
p1524
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cyclophosphamide'
p1525
sa(dp1526
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p1527
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1528
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIGOXIN'
p1529
sg27
Nsg28
S'In patients, the concomitant administration of digoxin with dofetilide was associated with a higher occurrence of torsade de pointes.| \r'
p1530
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOFETILIDE'
p1531
sa(dp1532
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01240'
p1533
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1534
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIGOXIN'
p1535
sg27
Nsg28
S'However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to digoxin toxicity.| In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.| \r'
p1536
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Flolan'
p1537
sa(dp1538
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1539
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1540
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIGOXIN'
p1541
sg27
Nsg28
S'It is, therefore, advisable to monitor digoxin concentrations in patients receiving ketoconazole.| \r'
p1542
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p1543
sa(dp1544
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00635'
p1545
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1546
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIGOXIN'
p1547
sg27
Nsg28
S'Reversible decreases in steady-state plasma digoxin concentrations and renal glycoside excretion were observed in patients receiving beta-acetyl digoxin and chemotherapy regimens containing cyclophosphamide, vincristine, and prednisone with or without cytarabine or procarbazine.| \r'
p1548
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PREDNISONE'
p1549
sa(dp1550
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00541'
p1551
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1552
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIGOXIN'
p1553
sg27
Nsg28
S'Reversible decreases in steady-state plasma digoxin concentrations and renal glycoside excretion were observed in patients receiving beta-acetyl digoxin and chemotherapy regimens containing cyclophosphamide, vincristine, and prednisone with or without cytarabine or procarbazine.| \r'
p1554
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VINCRISTINE'
p1555
sa(dp1556
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00998'
p1557
sg5
S'http://bio2rdf.org/drugbank:DB00320'
p1558
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIHYDROERGOTAMINE'
p1559
sg27
Nsg28
S'Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).| \r'
p1560
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Frova'
p1561
sa(dp1562
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00952'
p1563
sg5
S'http://bio2rdf.org/drugbank:DB00320'
p1564
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIHYDROERGOTAMINE'
p1565
sg27
Nsg28
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.| \r'
p1566
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NARATRIPTAN'
p1567
sa(dp1568
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p1569
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p1570
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DILTIAZEM'
p1571
sg27
Nsg28
S'Concomitant administration of diltiazem with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase), resulting in toxicity in some cases.| \r'
p1572
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CARBAMAZEPINE'
p1573
sa(dp1574
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p1575
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p1576
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DILTIAZEM'
p1577
sg27
Nsg28
S'Patients currently receiving diltiazem therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with cimetidine.| \r'
p1578
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIMETIDINE'
p1579
sa(dp1580
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p1581
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p1582
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DILTIAZEM'
p1583
sg27
Nsg28
S'A pharmacokinetic interaction between diltiazem and cyclosporine has been observed during studies involving renal and cardiac transplant patients.| \r'
p1584
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSPORINE'
p1585
sa(dp1586
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00813'
p1587
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p1588
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DILTIAZEM'
p1589
sg27
Nsg28
S'The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.| \r'
p1590
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FENTANYL'
p1591
sa(dp1592
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00227'
p1593
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p1594
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DILTIAZEM'
p1595
sg27
Nsg28
S'In a ten-subject study, coadministration of diltiazem (120 mg bid) with lovastatin resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs. lovastatin alone;| \r'
p1596
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LOVASTATIN'
p1597
sa(dp1598
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p1599
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p1600
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DILTIAZEM'
p1601
sg27
Nsg28
S'Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.| These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.| \r'
p1602
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIDAZOLAM'
p1603
sa(dp1604
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p1605
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p1606
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DILTIAZEM'
p1607
sg27
Nsg28
S'Coadministration of diltiazem with rifampin or any known CYP3A4 inducer should be avoided when possible, and alternative therapy considered.| \r'
p1608
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFAMPIN'
p1609
sa(dp1610
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p1611
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p1612
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DILTIAZEM'
p1613
sg27
Nsg28
S'Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| \r'
p1614
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tikosyn'
p1615
sa(dp1616
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00897'
p1617
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p1618
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DILTIAZEM'
p1619
sg27
Nsg28
S'Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.| These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.| \r'
p1620
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TRIAZOLAM'
p1621
sa(dp1622
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00714'
p1623
sg5
S'http://bio2rdf.org/drugbank:DB00985'
p1624
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIMENHYDRINATE'
p1625
sg27
Nsg28
S'Dimenhydrinate may decrease emetic response to apomorphine.| \r'
p1626
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'APOMORPHINE'
p1627
sa(dp1628
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p1629
sg5
S'http://bio2rdf.org/drugbank:DB01081'
p1630
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIPHENOXYLATE'
p1631
sg27
Nsg28
S'Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.| \r'
p1632
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p1633
sa(dp1634
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00640'
p1635
sg5
S'http://bio2rdf.org/drugbank:DB00975'
p1636
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIPYRIDAMOLE'
p1637
sg27
Nsg28
S'Adenosine: Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine.| \r'
p1638
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ADENOSINE'
p1639
sa(dp1640
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p1641
sg5
S'http://bio2rdf.org/drugbank:DB04817'
p1642
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIPYRONE'
p1643
sg27
Nsg28
S'Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.| \r'
p1644
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p1645
sa(dp1646
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p1647
sg5
S'http://bio2rdf.org/drugbank:DB00822'
p1648
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DISULFIRAM'
p1649
sg27
Nsg28
S'In some patients, a disulfiram-like reaction may be produced by the ingestion of alcohol.| Rare cases of a disulfiram-like reaction to alcohol have been reported.| \r'
p1650
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p1651
sa(dp1652
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p1653
sg5
S'http://bio2rdf.org/drugbank:DB00757'
p1654
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DOLASETRON'
p1655
sg27
Nsg28
S'Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.| \r'
p1656
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIMETIDINE'
p1657
sa(dp1658
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p1659
sg5
S'http://bio2rdf.org/drugbank:DB00757'
p1660
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DOLASETRON'
p1661
sg27
Nsg28
S'Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.| \r'
p1662
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFAMPIN'
p1663
sa(dp1664
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00321'
p1665
sg5
S'http://bio2rdf.org/drugbank:DB00476'
p1666
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DULOXETINE'
p1667
sg27
Nsg28
S'Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.| \r'
p1668
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMITRIPTYLINE'
p1669
sa(dp1670
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01151'
p1671
sg5
S'http://bio2rdf.org/drugbank:DB00476'
p1672
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DULOXETINE'
p1673
sg27
Nsg28
S'When duloxetine was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold.| \r'
p1674
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DESIPRAMINE'
p1675
sa(dp1676
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p1677
sg5
S'http://bio2rdf.org/drugbank:DB00476'
p1678
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DULOXETINE'
p1679
sg27
Nsg28
S'Inhibitors of CYP1A2: Concomitant use of duloxetine with fluvoxamine, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of duloxetine.| \r'
p1680
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p1681
sa(dp1682
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00458'
p1683
sg5
S'http://bio2rdf.org/drugbank:DB00476'
p1684
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DULOXETINE'
p1685
sg27
Nsg28
S'Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.| \r'
p1686
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'IMIPRAMINE'
p1687
sa(dp1688
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00540'
p1689
sg5
S'http://bio2rdf.org/drugbank:DB00476'
p1690
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DULOXETINE'
p1691
sg27
Nsg28
S'Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.| \r'
p1692
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NORTRIPTYLINE'
p1693
sa(dp1694
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p1695
sg5
S'http://bio2rdf.org/drugbank:DB00023'
p1696
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Elspar'
p1697
sg27
Nsg28
S'Tissue culture and animal studies indicate that ELSPAR can diminish or abolish the effect of methotrexate on malignant cells.14 This effect on methotrexate activity persists as long as plasma asparagine levels are suppressed.| \r'
p1698
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHOTREXATE'
p1699
sa(dp1700
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01211'
p1701
sg5
S'http://bio2rdf.org/drugbank:DB00496'
p1702
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Enablex'
p1703
sg27
Nsg28
S'The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .| \r'
p1704
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLARITHROMYCIN'
p1705
sa(dp1706
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1707
sg5
S'http://bio2rdf.org/drugbank:DB00496'
p1708
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Enablex'
p1709
sg27
Nsg28
S'The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .| \r'
p1710
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p1711
sa(dp1712
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB05251'
p1713
sg5
S'http://bio2rdf.org/drugbank:DB00496'
p1714
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Enablex'
p1715
sg27
Nsg28
S'The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .| \r'
p1716
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NELFINAVIR'
p1717
sa(dp1718
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p1719
sg5
S'http://bio2rdf.org/drugbank:DB00496'
p1720
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Enablex'
p1721
sg27
Nsg28
S'The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .| \r'
p1722
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p1723
sa(dp1724
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p1725
sg5
S'http://bio2rdf.org/drugbank:DB00584'
p1726
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ENALAPRIL'
p1727
sg27
Nsg28
S'A few cases of lithium toxicity have been reported in patients receiving concomitant enalapril/enalapril IV and lithium and were reversible upon discontinuation of both drugs.| It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.| \r'
p1728
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p1729
sa(dp1730
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p1731
sg5
S'http://bio2rdf.org/drugbank:DB00584'
p1732
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ENALAPRIL'
p1733
sg27
Nsg28
S'A few cases of lithium toxicity have been reported in patients receiving concomitant enalapril/enalapril IV and lithium and were reversible upon discontinuation of both drugs.| It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.| \r'
p1734
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p1735
sa(dp1736
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01294'
p1737
sg5
S'http://bio2rdf.org/drugbank:DB00467'
p1738
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ENOXACIN'
p1739
sg27
Nsg28
S'Thus, concomitant administration of enoxacin and bismuth subsalicylate should be avoided.| \r'
p1740
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BISMUTH SUBSALICYLATE'
p1741
sa(dp1742
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00201'
p1743
sg5
S'http://bio2rdf.org/drugbank:DB00467'
p1744
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ENOXACIN'
p1745
sg27
Nsg28
S'In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.| \r'
p1746
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CAFFEINE'
p1747
sa(dp1748
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p1749
sg5
S'http://bio2rdf.org/drugbank:DB00467'
p1750
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ENOXACIN'
p1751
sg27
Nsg28
S'If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.| \r'
p1752
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p1753
sa(dp1754
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00863'
p1755
sg5
S'http://bio2rdf.org/drugbank:DB00467'
p1756
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ENOXACIN'
p1757
sg27
Nsg28
S'The oral bioavailability of enoxacin is reduced by 60% with coadministration of ranitidine.| \r'
p1758
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RANITIDINE'
p1759
sa(dp1760
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p1761
sg5
S'http://bio2rdf.org/drugbank:DB00467'
p1762
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ENOXACIN'
p1763
sg27
Nsg28
S'Enoxacin interferes with the metabolism of theophylline resulting in a 42% to 74% dose-related decrease in theophylline clearance and a subsequent 260% to 350% increase in serum theophylline levels.| \r'
p1764
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p1765
sa(dp1766
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00261'
p1767
sg5
S'http://bio2rdf.org/drugbank:DB04880'
p1768
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ENOXIMONE'
p1769
sg27
Nsg28
S'The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.| \r'
p1770
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ANAGRELIDE'
p1771
sa(dp1772
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01170'
p1773
sg5
S'http://bio2rdf.org/drugbank:DB00668'
p1774
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'EPINEPHRINE'
p1775
sg27
Nsg28
S'Epinephrine may antagonize the neuron blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter.| \r'
p1776
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GUANETHIDINE'
p1777
sa(dp1778
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01064'
p1779
sg5
S'http://bio2rdf.org/drugbank:DB00668'
p1780
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'EPINEPHRINE'
p1781
sg27
Nsg28
S'Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.| \r'
p1782
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Isoproterenol'
p1783
sa(dp1784
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01361'
p1785
sg5
S'http://bio2rdf.org/drugbank:DB00696'
p1786
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ergomar'
p1787
sg27
Nsg28
S'The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.| \r'
p1788
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Triacetyloleandomycin'
p1789
sa(dp1790
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00998'
p1791
sg5
S'http://bio2rdf.org/drugbank:DB00696'
p1792
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ERGOTAMINE'
p1793
sg27
Nsg28
S'Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).| \r'
p1794
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Frova'
p1795
sa(dp1796
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00952'
p1797
sg5
S'http://bio2rdf.org/drugbank:DB00696'
p1798
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ERGOTAMINE'
p1799
sg27
Nsg28
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.| \r'
p1800
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NARATRIPTAN'
p1801
sa(dp1802
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00802'
p1803
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p1804
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p1805
sg27
Nsg28
S'Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| \r'
p1806
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALFENTANIL'
p1807
sa(dp1808
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p1809
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p1810
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p1811
sg27
Nsg28
S'Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.| Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| \r'
p1812
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASTEMIZOLE'
p1813
sa(dp1814
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p1815
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p1816
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p1817
sg27
Nsg28
S'On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.| \r'
p1818
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BEXAROTENE'
p1819
sa(dp1820
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01200'
p1821
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p1822
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p1823
sg27
Nsg28
S'Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| \r'
p1824
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BROMOCRIPTINE'
p1825
sa(dp1826
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p1827
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p1828
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p1829
sg27
Nsg28
S'Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| \r'
p1830
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CARBAMAZEPINE'
p1831
sa(dp1832
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01166'
p1833
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p1834
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p1835
sg27
Nsg28
S'Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.| \r'
p1836
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CILOSTAZOL'
p1837
sa(dp1838
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p1839
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p1840
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p1841
sg27
Nsg28
S'Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| \r'
p1842
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p1843
sa(dp1844
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00363'
p1845
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p1846
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p1847
sg27
Nsg28
S'Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.| \r'
p1848
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLOZAPINE'
p1849
sa(dp1850
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p1851
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p1852
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p1853
sg27
Nsg28
S'Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| \r'
p1854
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSPORINE'
p1855
sa(dp1856
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p1857
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p1858
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p1859
sg27
Nsg28
S'Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.| Digoxin Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.| Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.| \r'
p1860
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p1861
sa(dp1862
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00320'
p1863
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p1864
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p1865
sg27
Nsg28
S'Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.| Ergotamine Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.| \r'
p1866
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIHYDROERGOTAMINE'
p1867
sa(dp1868
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00696'
p1869
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p1870
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p1871
sg27
Nsg28
S'Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.| Ergotamine Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.| \r'
p1872
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERGOTAMINE'
p1873
sa(dp1874
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00813'
p1875
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p1876
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p1877
sg27
Nsg28
S'The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.| \r'
p1878
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FENTANYL'
p1879
sa(dp1880
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00455'
p1881
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p1882
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p1883
sg27
Nsg28
S'Plasma concentrations (AUC 0-24 hrs) of erythromycin decreased 15% with coadministration of loratadine relative to that observed with erythromycin alone.| \r'
p1884
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LORATADINE'
p1885
sa(dp1886
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00227'
p1887
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p1888
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p1889
sg27
Nsg28
S'Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| \r'
p1890
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LOVASTATIN'
p1891
sa(dp1892
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p1893
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p1894
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p1895
sg27
Nsg28
S'Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.| \r'
p1896
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIDAZOLAM'
p1897
sa(dp1898
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p1899
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p1900
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p1901
sg27
Nsg28
S'Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| \r'
p1902
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p1903
sa(dp1904
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00864'
p1905
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p1906
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p1907
sg27
Nsg28
S'There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| \r'
p1908
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TACROLIMUS ANHYDROUS'
p1909
sa(dp1910
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00864'
p1911
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p1912
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p1913
sg27
Nsg28
S'There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| \r'
p1914
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TACROLIMUS'
p1915
sa(dp1916
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p1917
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p1918
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p1919
sg27
Nsg28
S'Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.| \r'
p1920
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p1921
sa(dp1922
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00897'
p1923
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p1924
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p1925
sg27
Nsg28
S'Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.| \r'
p1926
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TRIAZOLAM'
p1927
sa(dp1928
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p1929
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p1930
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ERYTHROMYCIN'
p1931
sg27
Nsg28
S'Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| \r'
p1932
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Valproate'
p1933
sa(dp1934
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01060'
p1935
sg5
S'http://bio2rdf.org/drugbank:DB00736'
p1936
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ESOMEPRAZOLE'
p1937
sg27
Nsg28
S'Combination Therapy with Clarithromycin Co-administration of esomeprazole, clarithromycin, and amoxicillin has resulted in increases in the plasma levels of esomeprazole and 14-hydroxyclarithromycin.| \r'
p1938
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMOXICILLIN ANHYDROUS'
p1939
sa(dp1940
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01060'
p1941
sg5
S'http://bio2rdf.org/drugbank:DB00736'
p1942
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ESOMEPRAZOLE'
p1943
sg27
Nsg28
S'Combination Therapy with Clarithromycin Co-administration of esomeprazole, clarithromycin, and amoxicillin has resulted in increases in the plasma levels of esomeprazole and 14-hydroxyclarithromycin.| \r'
p1944
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMOXICILLIN'
p1945
sa(dp1946
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01211'
p1947
sg5
S'http://bio2rdf.org/drugbank:DB00736'
p1948
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ESOMEPRAZOLE'
p1949
sg27
Nsg28
S'Combination Therapy with Clarithromycin Co-administration of esomeprazole, clarithromycin, and amoxicillin has resulted in increases in the plasma levels of esomeprazole and 14-hydroxyclarithromycin.| \r'
p1950
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLARITHROMYCIN'
p1951
sa(dp1952
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p1953
sg5
S'http://bio2rdf.org/drugbank:DB00736'
p1954
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ESOMEPRAZOLE'
p1955
sg27
Nsg28
S'Coadministration of esomeprazole 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam.| \r'
p1956
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIAZEPAM'
p1957
sa(dp1958
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p1959
sg5
S'http://bio2rdf.org/drugbank:DB00736'
p1960
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ESOMEPRAZOLE'
p1961
sg27
Nsg28
S'Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).| \r'
p1962
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p1963
sa(dp1964
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1965
sg5
S'http://bio2rdf.org/drugbank:DB00736'
p1966
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ESOMEPRAZOLE'
p1967
sg27
Nsg28
S'Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).| \r'
p1968
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p1969
sa(dp1970
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1971
sg5
S'http://bio2rdf.org/drugbank:DB01215'
p1972
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ESTAZOLAM'
p1973
sg27
Nsg28
S'Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A.| \r'
p1974
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p1975
sa(dp1976
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p1977
sg5
S'http://bio2rdf.org/drugbank:DB00402'
p1978
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ESZOPICLONE'
p1979
sg27
Nsg28
S'CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.| \r'
p1980
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p1981
sa(dp1982
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1983
sg5
S'http://bio2rdf.org/drugbank:DB00402'
p1984
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ESZOPICLONE'
p1985
sg27
Nsg28
S'The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days.| \r'
p1986
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p1987
sa(dp1988
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00260'
p1989
sg5
S'http://bio2rdf.org/drugbank:DB00609'
p1990
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETHIONAMIDE'
p1991
sg27
Nsg28
S'In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs.| \r'
p1992
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSERINE'
p1993
sa(dp1994
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01035'
p1995
sg5
S'http://bio2rdf.org/drugbank:DB00311'
p1996
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETHOXZOLAMIDE'
p1997
sg27
Nsg28
S'Ethoxzolamide may increase the action of tricyclics, amphetamines, procainamide, and quinidine.| \r'
p1998
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROCAINAMIDE'
p1999
sa(dp2000
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p2001
sg5
S'http://bio2rdf.org/drugbank:DB00311'
p2002
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETHOXZOLAMIDE'
p2003
sg27
Nsg28
S'Ethoxzolamide may increase the action of tricyclics, amphetamines, procainamide, and quinidine.| \r'
p2004
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'QUINIDINE'
p2005
sa(dp2006
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00654'
p2007
sg5
S'http://bio2rdf.org/drugbank:DB02731'
p2008
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETHYLMERCURITHIOSALICYLIC ACID'
p2009
sg27
Nsg28
S'In vitro studies have shown that precipitation occurs when eye drops containing thimerosal are mixed with latanoprost.| \r'
p2010
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LATANOPROST'
p2011
sa(dp2012
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00812'
p2013
sg5
S'http://bio2rdf.org/drugbank:DB00749'
p2014
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Etodolac'
p2015
sg27
Nsg28
S'Although in vivo studies have not been done to see if etodolac clearance is changed by coadministration of phenylbutazone, it is not recommended that they be coadministered.| \r'
p2016
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYLBUTAZONE'
p2017
sa(dp2018
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p2019
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2020
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2021
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2022
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACETAMINOPHEN'
p2023
sa(dp2024
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p2025
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2026
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2027
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2028
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ADENOSINE PHOSPHATE'
p2029
sa(dp2030
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00701'
p2031
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2032
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2033
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2034
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Agenerase'
p2035
sa(dp2036
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p2037
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2038
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2039
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2040
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPICILLIN'
p2041
sa(dp2042
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00126'
p2043
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2044
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2045
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2046
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASCORBIC ACID'
p2047
sa(dp2048
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01076'
p2049
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2050
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2051
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2052
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ATORVASTATIN'
p2053
sa(dp2054
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00636'
p2055
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2056
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2057
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2058
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Atromid-S'
p2059
sa(dp2060
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00636'
p2061
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2062
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2063
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2064
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLOFIBRATE'
p2065
sa(dp2066
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p2067
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2068
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2069
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2070
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Crixivan'
p2071
sa(dp2072
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p2073
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2074
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2075
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2076
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSPORINE'
p2077
sa(dp2078
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p2079
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2080
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2081
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2082
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Dilantin'
p2083
sa(dp2084
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00949'
p2085
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2086
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2087
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2088
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Felbatol'
p2089
sa(dp2090
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p2091
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2092
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2093
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2094
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Fortovase'
p2095
sa(dp2096
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00400'
p2097
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2098
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2099
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2100
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Gris-PEG'
p2101
sa(dp2102
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p2103
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2104
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2105
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2106
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Invirase'
p2107
sa(dp2108
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p2109
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2110
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2111
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2112
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Kadian'
p2113
sa(dp2114
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01076'
p2115
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2116
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2117
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2118
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Lipitor'
p2119
sa(dp2120
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p2121
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2122
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2123
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2124
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MORPHINE'
p2125
sa(dp2126
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p2127
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2128
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2129
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2130
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MS Contin'
p2131
sa(dp2132
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p2133
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2134
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2135
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2136
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Neoral '
p2137
sa(dp2138
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p2139
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2140
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2141
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2142
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nizoral'
p2143
sa(dp2144
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p2145
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2146
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2147
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2148
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Norvir'
p2149
sa(dp2150
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p2151
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2152
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2153
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2154
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p2155
sa(dp2156
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00812'
p2157
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2158
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2159
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2160
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYLBUTAZONE'
p2161
sa(dp2162
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00860'
p2163
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2164
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2165
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2166
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PREDNISOLONE'
p2167
sa(dp2168
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00860'
p2169
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2170
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2171
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2172
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Prelone'
p2173
sa(dp2174
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p2175
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2176
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2177
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2178
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Rifadin'
p2179
sa(dp2180
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p2181
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2182
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2183
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2184
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFAMPIN'
p2185
sa(dp2186
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p2187
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2188
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2189
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2190
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sandimmune '
p2191
sa(dp2192
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01167'
p2193
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2194
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2195
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2196
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sporanox'
p2197
sa(dp2198
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p2199
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2200
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2201
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2202
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TEGretol'
p2203
sa(dp2204
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00759'
p2205
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2206
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2207
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2208
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TETRACYCLINE'
p2209
sa(dp2210
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p2211
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2212
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2213
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2214
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Theo-Dur'
p2215
sa(dp2216
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p2217
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2218
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2219
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2220
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p2221
sa(dp2222
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00273'
p2223
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2224
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2225
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2226
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Topamax'
p2227
sa(dp2228
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00776'
p2229
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2230
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2231
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2232
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Trileptal'
p2233
sa(dp2234
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p2235
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2236
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2237
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2238
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tylenol'
p2239
sa(dp2240
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p2241
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2242
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p2243
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2244
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Viracept'
p2245
sa(dp2246
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB06730'
p2247
sg5
S'http://bio2rdf.org/drugbank:DB00949'
p2248
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'FELBAMATE'
p2249
sg27
Nsg28
S'Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol.| \r'
p2250
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GESTODENE'
p2251
sa(dp2252
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p2253
sg5
S'http://bio2rdf.org/drugbank:DB00949'
p2254
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'FELBAMATE'
p2255
sg27
Nsg28
S'This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol? Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.| \r'
p2256
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p2257
sa(dp2258
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p2259
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p2260
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'FENTANYL'
p2261
sg27
Nsg28
S'Central Nervous System Depressants The concomitant use of DURAGESIC? (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.| \r'
p2262
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p2263
sa(dp2264
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01211'
p2265
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p2266
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'FENTANYL'
p2267
sg27
Nsg28
S'The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| \r'
p2268
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLARITHROMYCIN'
p2269
sa(dp2270
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p2271
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p2272
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'FENTANYL'
p2273
sg27
Nsg28
S'The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| \r'
p2274
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p2275
sa(dp2276
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB05251'
p2277
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p2278
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'FENTANYL'
p2279
sg27
Nsg28
S'The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| \r'
p2280
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NELFINAVIR'
p2281
sa(dp2282
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p2283
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p2284
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'FENTANYL'
p2285
sg27
Nsg28
S'The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| \r'
p2286
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p2287
sa(dp2288
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p2289
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p2290
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'FENTANYL'
p2291
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p2292
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p2293
sa(dp2294
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p2295
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p2296
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'FENTANYL'
p2297
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p2298
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p2299
sa(dp2300
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01361'
p2301
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p2302
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'FENTANYL'
p2303
sg27
Nsg28
S'The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| \r'
p2304
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TROLEANDOMYCIN'
p2305
sa(dp2306
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p2307
sg5
S'http://bio2rdf.org/drugbank:DB00924'
p2308
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Flexeril'
p2309
sg27
Nsg28
S'FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.| \r'
p2310
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p2311
sa(dp2312
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00482'
p2313
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p2314
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'FLUCONAZOLE'
p2315
sg27
Nsg28
S'Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.| \r'
p2316
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CELECOXIB'
p2317
sa(dp2318
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p2319
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p2320
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'FLUCONAZOLE'
p2321
sg27
Nsg28
S'Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| \r'
p2322
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p2323
sa(dp2324
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p2325
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p2326
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'FLUCONAZOLE'
p2327
sg27
Nsg28
S'Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.| \r'
p2328
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p2329
sa(dp2330
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00552'
p2331
sg5
S'http://bio2rdf.org/drugbank:DB01073'
p2332
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Fludara'
p2333
sg27
Nsg28
S'The use of FLUDARA FOR INJECTION in combination with pentostatin is not recommended due to the risk of severe pulmonary toxicity.| \r'
p2334
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PENTOSTATIN'
p2335
sa(dp2336
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01199'
p2337
sg5
S'http://bio2rdf.org/drugbank:DB01159'
p2338
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Fluothane'
p2339
sg27
Nsg28
S'FLUOTHANE may augment the hypotension caused by the ganglionic-blocking effect of tubocurarine.| \r'
p2340
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TUBOCURARINE'
p2341
sa(dp2342
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p2343
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p2344
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p2345
sg27
Nsg28
S'Alprazolam: When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;| Although it has not been definitively demonstrated that fluvoxamine is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of fluvoxamine with alprazolam.| \r'
p2346
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALPRAZOLAM'
p2347
sa(dp2348
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p2349
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p2350
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p2351
sg27
Nsg28
S'Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.| \r'
p2352
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASTEMIZOLE'
p2353
sa(dp2354
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p2355
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p2356
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p2357
sg27
Nsg28
S'Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.| \r'
p2358
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p2359
sa(dp2360
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p2361
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p2362
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p2363
sg27
Nsg28
S'Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.| Diazepam: The co-administration of Fluvoxamine Tablets and diazepam is generally not advisable.| Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.| \r'
p2364
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIAZEPAM'
p2365
sa(dp2366
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00857'
p2367
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p2368
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p2369
sg27
Nsg28
S'Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.| \r'
p2370
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TERBINAFINE'
p2371
sa(dp2372
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00681'
p2373
sg5
S'http://bio2rdf.org/drugbank:DB00529'
p2374
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Foscavir'
p2375
sg27
Nsg28
S'Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.| \r'
p2376
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPHOTERICIN B'
p2377
sa(dp2378
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00738'
p2379
sg5
S'http://bio2rdf.org/drugbank:DB00529'
p2380
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Foscavir'
p2381
sg27
Nsg28
S'A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.| Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;| \r'
p2382
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Pentamidin'
p2383
sa(dp2384
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p2385
sg5
S'http://bio2rdf.org/drugbank:DB00695'
p2386
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'FUROSEMIDE'
p2387
sg27
Nsg28
S'Tablets, Injection, and Oral Solution One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency.| \r'
p2388
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p2389
sa(dp2390
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00903'
p2391
sg5
S'http://bio2rdf.org/drugbank:DB00695'
p2392
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'FUROSEMIDE'
p2393
sg27
Nsg28
S'Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity.| \r'
p2394
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ETHACRYNIC ACID'
p2395
sa(dp2396
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01240'
p2397
sg5
S'http://bio2rdf.org/drugbank:DB00695'
p2398
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'FUROSEMIDE'
p2399
sg27
Nsg28
S'In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.| \r'
p2400
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Flolan'
p2401
sa(dp2402
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00368'
p2403
sg5
S'http://bio2rdf.org/drugbank:DB00695'
p2404
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'FUROSEMIDE'
p2405
sg27
Nsg28
S'Furosemide may decrease arterial responsiveness to norepinephrine.| \r'
p2406
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NOREPINEPHRINE'
p2407
sa(dp2408
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01199'
p2409
sg5
S'http://bio2rdf.org/drugbank:DB00695'
p2410
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'FUROSEMIDE'
p2411
sg27
Nsg28
S'Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.| \r'
p2412
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TUBOCURARINE'
p2413
sa(dp2414
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p2415
sg5
S'http://bio2rdf.org/drugbank:DB00996'
p2416
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'GABAPENTIN'
p2417
sg27
Nsg28
S'This small decrease in excretion of gabapentin by cimetidine is not expected to be of clinical importance.| \r'
p2418
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIMETIDINE'
p2419
sa(dp2420
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p2421
sg5
S'http://bio2rdf.org/drugbank:DB01241'
p2422
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'GEMFIBROZIL'
p2423
sg27
Nsg28
S'Concomitant administration of Targretin ? capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.| \r'
p2424
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BEXAROTENE'
p2425
sa(dp2426
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p2427
sg5
S'http://bio2rdf.org/drugbank:DB01241'
p2428
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'GEMFIBROZIL'
p2429
sg27
Nsg28
S'Concomitant administration of gemfibrozil with Targretin ? capsules is not recommended.| \r'
p2430
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Targretin'
p2431
sa(dp2432
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p2433
sg5
S'http://bio2rdf.org/drugbank:DB00619'
p2434
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Gleevec'
p2435
sg27
Nsg28
S'in vitro, Gleevec inhibits acetaminophen O-glucuronidation (Ki value of 58.5 ?M) at therapeutic levels.| \r'
p2436
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACETAMINOPHEN'
p2437
sa(dp2438
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p2439
sg5
S'http://bio2rdf.org/drugbank:DB00619'
p2440
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Gleevec'
p2441
sg27
Nsg28
S'Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).| \r'
p2442
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSPORINE'
p2443
sa(dp2444
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p2445
sg5
S'http://bio2rdf.org/drugbank:DB00619'
p2446
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Gleevec'
p2447
sg27
Nsg28
S'Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).| \r'
p2448
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERYTHROMYCIN'
p2449
sa(dp2450
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p2451
sg5
S'http://bio2rdf.org/drugbank:DB00619'
p2452
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Gleevec'
p2453
sg27
Nsg28
S'Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).| There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).| \r'
p2454
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p2455
sa(dp2456
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00641'
p2457
sg5
S'http://bio2rdf.org/drugbank:DB00619'
p2458
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Gleevec'
p2459
sg27
Nsg28
S'Drugs that may have their plasma concentration altered by Gleevec Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.| \r'
p2460
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SIMVASTATIN'
p2461
sa(dp2462
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p2463
sg5
S'http://bio2rdf.org/drugbank:DB01067'
p2464
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'GLIPIZIDE'
p2465
sg27
Nsg28
S'The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).| \r'
p2466
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p2467
sa(dp2468
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00328'
p2469
sg5
S'http://bio2rdf.org/drugbank:DB00130'
p2470
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'GLUTAMINE'
p2471
sg27
Nsg28
S'Indomethacin - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by indomethacin.| Indomethacin - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by indomethacin.| \r'
p2472
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDOMETHACIN'
p2473
sa(dp2474
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01229'
p2475
sg5
S'http://bio2rdf.org/drugbank:DB00130'
p2476
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'GLUTAMINE'
p2477
sg27
Nsg28
S'Paclitaxel - In one report, L-glutamine at a dose of 10 grams three times daily, given 24 hours after receiving paclitaxel, appeared to prevent the development of myalgia and arthralgia, adverse reactions of paclitaxel.| \r'
p2478
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PACLITAXEL'
p2479
sa(dp2480
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00328'
p2481
sg5
S'http://bio2rdf.org/drugbank:DB02174'
p2482
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'GLUTAMINE'
p2483
sg27
Nsg28
S'Indomethacin - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by indomethacin.| Indomethacin - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by indomethacin.| \r'
p2484
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDOMETHACIN'
p2485
sa(dp2486
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00537'
p2487
sg5
S'http://bio2rdf.org/drugbank:DB01016'
p2488
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'GLYBURIDE'
p2489
sg27
Nsg28
S'A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.| \r'
p2490
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIPROFLOXACIN'
p2491
sa(dp2492
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00612'
p2493
sg5
S'http://bio2rdf.org/drugbank:DB01170'
p2494
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'GUANETHIDINE'
p2495
sg27
Nsg28
S'Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.| \r'
p2496
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Zebeta'
p2497
sa(dp2498
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p2499
sg5
S'http://bio2rdf.org/drugbank:DB01018'
p2500
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'GUANFACINE'
p2501
sg27
Nsg28
S'The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.| \r'
p2502
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p2503
sa(dp2504
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00988'
p2505
sg5
S'http://bio2rdf.org/drugbank:DB00502'
p2506
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'HALOPERIDOL'
p2507
sg27
Nsg28
S'Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.| Haloperidol: Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines.| \r'
p2508
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOPAMINE'
p2509
sa(dp2510
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00368'
p2511
sg5
S'http://bio2rdf.org/drugbank:DB00502'
p2512
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'HALOPERIDOL'
p2513
sg27
Nsg28
S'Haloperidol: Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines.| \r'
p2514
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NOREPINEPHRINE'
p2515
sa(dp2516
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00384'
p2517
sg5
S'http://bio2rdf.org/drugbank:DB00999'
p2518
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'HCTZ'
p2519
sg27
Nsg28
S'Hydrochlorothiazide (HCTZ) Alone or in Combination with Triamterene: Concomitant use of HCTZ alone or in combination with triamterene is contraindicated.| In patients receiving HCTZ in combination with triamterene, dofetilide AUC increased by 30% and Cmax by 16%.| \r'
p2520
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TRIAMTERENE'
p2521
sa(dp2522
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00996'
p2523
sg5
S'http://bio2rdf.org/drugbank:DB00956'
p2524
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'HYDROCODONE'
p2525
sg27
Nsg28
S'Hydrocodone increases gabapentin AUC values by 14%.| \r'
p2526
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GABAPENTIN'
p2527
sa(dp2528
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p2529
sg5
S'http://bio2rdf.org/drugbank:DB00458'
p2530
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'IMIPRAMINE'
p2531
sg27
Nsg28
S'The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.| \r'
p2532
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALPRAZOLAM'
p2533
sa(dp2534
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00701'
p2535
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p2536
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'INDINAVIR ANHYDROUS'
p2537
sg27
Nsg28
S'Indinavir steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant amprenavir.| \r'
p2538
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPRENAVIR'
p2539
sa(dp2540
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p2541
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p2542
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'INDINAVIR ANHYDROUS'
p2543
sg27
Nsg28
S'Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| \r'
p2544
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p2545
sa(dp2546
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p2547
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p2548
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'INDINAVIR ANHYDROUS'
p2549
sg27
Nsg28
S'Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.| \r'
p2550
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIDANOSINE'
p2551
sa(dp2552
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00238'
p2553
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p2554
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'INDINAVIR ANHYDROUS'
p2555
sg27
Nsg28
S'Indinavir concentrations may be decreased in the presence of nevirapine.| \r'
p2556
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NEVIRAPINE'
p2557
sa(dp2558
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p2559
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p2560
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'INDINAVIR ANHYDROUS'
p2561
sg27
Nsg28
S'Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving indinavir in combination with ritonavir than those receiving CRIXIVAN 800 mg q8h.| \r'
p2562
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p2563
sa(dp2564
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p2565
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p2566
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'INDINAVIR ANHYDROUS'
p2567
sg27
Nsg28
S'Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.| To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.| \r'
p2568
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Videx'
p2569
sa(dp2570
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00701'
p2571
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p2572
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'INDINAVIR'
p2573
sg27
Nsg28
S'Indinavir steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant amprenavir.| \r'
p2574
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPRENAVIR'
p2575
sa(dp2576
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p2577
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p2578
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'INDINAVIR'
p2579
sg27
Nsg28
S'Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| \r'
p2580
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p2581
sa(dp2582
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p2583
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p2584
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'INDINAVIR'
p2585
sg27
Nsg28
S'Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.| \r'
p2586
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIDANOSINE'
p2587
sa(dp2588
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00238'
p2589
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p2590
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'INDINAVIR'
p2591
sg27
Nsg28
S'Indinavir concentrations may be decreased in the presence of nevirapine.| \r'
p2592
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NEVIRAPINE'
p2593
sa(dp2594
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p2595
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p2596
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'INDINAVIR'
p2597
sg27
Nsg28
S'Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving indinavir in combination with ritonavir than those receiving CRIXIVAN 800 mg q8h.| \r'
p2598
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p2599
sa(dp2600
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p2601
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p2602
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'INDINAVIR'
p2603
sg27
Nsg28
S'Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.| To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.| \r'
p2604
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Videx'
p2605
sa(dp2606
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB04630'
p2607
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p2608
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'INDOMETHACIN'
p2609
sg27
Nsg28
S'Indomethacin may also affect plasma renin levels, aldosterone excretion, and renin profile evaluation.| \r'
p2610
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALDOSTERONE'
p2611
sa(dp2612
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00887'
p2613
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p2614
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'INDOMETHACIN'
p2615
sg27
Nsg28
S'- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.| \r'
p2616
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BUMETANIDE'
p2617
sa(dp2618
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01197'
p2619
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p2620
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'INDOMETHACIN'
p2621
sg27
Nsg28
S'Inhibitors Of Endogenous Prostaglandin Synthesis It has been reported that indomethacin may reduce the antihypertensive effect of captopril, especially in cases of low renin hypertension.| \r'
p2622
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CAPTOPRIL'
p2623
sa(dp2624
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00861'
p2625
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p2626
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'INDOMETHACIN'
p2627
sg27
Nsg28
S'In some patients the combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage.| Therefore, indomethacin and diflunisal should not be used concomitantly.| \r'
p2628
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIFLUNISAL'
p2629
sa(dp2630
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p2631
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p2632
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'INDOMETHACIN'
p2633
sg27
Nsg28
S'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| \r'
p2634
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p2635
sa(dp2636
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p2637
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p2638
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'INDOMETHACIN'
p2639
sg27
Nsg28
S'Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis.| Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.| \r'
p2640
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FUROSEMIDE'
p2641
sa(dp2642
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00041'
p2643
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p2644
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'INDOMETHACIN'
p2645
sg27
Nsg28
S'Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.| \r'
p2646
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Proleukin'
p2647
sa(dp2648
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p2649
sg5
S'http://bio2rdf.org/drugbank:DB01232'
p2650
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Invirase'
p2651
sg27
Nsg28
S'Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered.| \r'
p2652
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p2653
sa(dp2654
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01258'
p2655
sg5
S'http://bio2rdf.org/drugbank:DB01029'
p2656
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'IRBESARTAN'
p2657
sg27
Nsg28
S'Co-administration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.| \r'
p2658
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALISKIREN'
p2659
sa(dp2660
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00565'
p2661
sg5
S'http://bio2rdf.org/drugbank:DB00753'
p2662
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Isoflurane'
p2663
sg27
Nsg28
S'In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.| \r'
p2664
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nimbex'
p2665
sa(dp2666
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p2667
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p2668
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ISONIAZID'
p2669
sg27
Nsg28
S'Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites.| It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed.| \r'
p2670
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACETAMINOPHEN'
p2671
sa(dp2672
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p2673
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p2674
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ISONIAZID'
p2675
sg27
Nsg28
S'Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.| \r'
p2676
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CARBAMAZEPINE'
p2677
sa(dp2678
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p2679
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p2680
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ISONIAZID'
p2681
sg27
Nsg28
S'INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.| \r'
p2682
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p2683
sa(dp2684
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01235'
p2685
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p2686
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ISONIAZID'
p2687
sg27
Nsg28
S'Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.| \r'
p2688
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LEVODOPA'
p2689
sa(dp2690
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p2691
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p2692
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ISONIAZID'
p2693
sg27
Nsg28
S'Phenytoin: Isoniazid may increase serum levels of phenytoin.| \r'
p2694
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p2695
sa(dp2696
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p2697
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p2698
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ISONIAZID'
p2699
sg27
Nsg28
S'Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid.| \r'
p2700
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p2701
sa(dp2702
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p2703
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p2704
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ISONIAZID'
p2705
sg27
Nsg28
S'Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.| \r'
p2706
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Valproate'
p2707
sa(dp2708
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01258'
p2709
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2710
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ketoconazole'
p2711
sg27
Nsg28
S'Ketoconazole Co-administration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.| \r'
p2712
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALISKIREN'
p2713
sa(dp2714
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p2715
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2716
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ketoconazole'
p2717
sg27
Nsg28
S'10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.| \r'
p2718
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'APREPITANT'
p2719
sa(dp2720
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01238'
p2721
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2722
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ketoconazole'
p2723
sg27
Nsg28
S'Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.| When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.| \r'
p2724
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ARIPIPRAZOLE'
p2725
sa(dp2726
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p2727
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2728
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ketoconazole'
p2729
sg27
Nsg28
S'Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.| \r'
p2730
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASTEMIZOLE'
p2731
sa(dp2732
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p2733
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2734
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ketoconazole'
p2735
sg27
Nsg28
S'On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.| \r'
p2736
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BEXAROTENE'
p2737
sa(dp2738
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01410'
p2739
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2740
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ketoconazole'
p2741
sg27
Nsg28
S'Therefore, ketoconazole should be administered with caution with intranasal ciclesonide.| \r'
p2742
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CICLESONIDE'
p2743
sa(dp2744
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p2745
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2746
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ketoconazole'
p2747
sg27
Nsg28
S'Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.| Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.| Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.| Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.| Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.| \r'
p2748
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p2749
sa(dp2750
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p2751
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2752
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ketoconazole'
p2753
sg27
Nsg28
S'Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.| \r'
p2754
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSPORINE'
p2755
sa(dp2756
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00951'
p2757
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2758
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ketoconazole'
p2759
sg27
Nsg28
S'Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist.| When Ketoconazole is given in combination with isoniazid and rifampin the AUC of ketoconazole is decreased by as much as 88% after 5 months of concurrent Isoniazid and Rifampin therapy.| \r'
p2760
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ISONIAZID'
p2761
sa(dp2762
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p2763
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2764
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ketoconazole'
p2765
sg27
Nsg28
S'Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.| \r'
p2766
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHYLPREDNISOLONE'
p2767
sa(dp2768
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p2769
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2770
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ketoconazole'
p2771
sg27
Nsg28
S'Concomitant administration of ketoconazole tablets with phenytoin may alter the metabolism of one or both of the drugs.| \r'
p2772
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p2773
sa(dp2774
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01012'
p2775
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2776
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ketoconazole'
p2777
sg27
Nsg28
S'Co-administration of ketoconazole, a strong inhibitor of CYP3A4, increased cinacalcet exposure following a single 90 mg dose of Sensipar by 2.3 fold.| \r'
p2778
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sensipar'
p2779
sa(dp2780
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p2781
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2782
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ketoconazole'
p2783
sg27
Nsg28
S'Ketoconazole at 400 mg daily (the maximum approved prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide Cmax by 53% in males and 97% in females, and AUC by 41% in males and 69% in females.| \r'
p2784
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tikosyn'
p2785
sa(dp2786
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00962'
p2787
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2788
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ketoconazole'
p2789
sg27
Nsg28
S'Other strong selective CYP3A4 inhibitors such as ketoconazole can also be expected to increase the exposure of zaleplon.| \r'
p2790
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZALEPLON'
p2791
sa(dp2792
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p2793
sg5
S'http://bio2rdf.org/drugbank:DB00709'
p2794
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'LAMIVUDINE'
p2795
sg27
Nsg28
S'Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.| Therefore, use of lamivudine in combination with zalcitabine is not recommended| \r'
p2796
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZALCITABINE'
p2797
sa(dp2798
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p2799
sg5
S'http://bio2rdf.org/drugbank:DB00448'
p2800
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Lansoprazole'
p2801
sg27
Nsg28
S'therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).| \r'
p2802
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ADENOSINE PHOSPHATE'
p2803
sa(dp2804
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p2805
sg5
S'http://bio2rdf.org/drugbank:DB00448'
p2806
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Lansoprazole'
p2807
sg27
Nsg28
S'therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).| \r'
p2808
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPICILLIN'
p2809
sa(dp2810
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p2811
sg5
S'http://bio2rdf.org/drugbank:DB00448'
p2812
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Lansoprazole'
p2813
sg27
Nsg28
S'When lansoprazole was administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen.| \r'
p2814
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p2815
sa(dp2816
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p2817
sg5
S'http://bio2rdf.org/drugbank:DB01002'
p2818
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'LEVOBUPIVACAINE'
p2819
sg27
Nsg28
S'Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;| \r'
p2820
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p2821
sa(dp2822
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p2823
sg5
S'http://bio2rdf.org/drugbank:DB01235'
p2824
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'LEVODOPA'
p2825
sg27
Nsg28
S'In addition, the beneficial effects of levodopa in Parkinsons disease have been reported to be reversed by phenytoin and papaverine.| \r'
p2826
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p2827
sa(dp2828
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p2829
sg5
S'http://bio2rdf.org/drugbank:DB00854'
p2830
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Levo-Dromoran'
p2831
sg27
Nsg28
S'Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.| \r'
p2832
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p2833
sa(dp2834
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00502'
p2835
sg5
S'http://bio2rdf.org/drugbank:DB00424'
p2836
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Levsin'
p2837
sg27
Nsg28
S'Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.| \r'
p2838
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HALOPERIDOL'
p2839
sa(dp2840
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p2841
sg5
S'http://bio2rdf.org/drugbank:DB01175'
p2842
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Lexapro'
p2843
sg27
Nsg28
S'Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.| \r'
p2844
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p2845
sa(dp2846
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p2847
sg5
S'http://bio2rdf.org/drugbank:DB01175'
p2848
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Lexapro'
p2849
sg27
Nsg28
S'Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.| \r'
p2850
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p2851
sa(dp2852
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p2853
sg5
S'http://bio2rdf.org/drugbank:DB01175'
p2854
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Lexapro'
p2855
sg27
Nsg28
S'Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.| \r'
p2856
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p2857
sa(dp2858
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p2859
sg5
S'http://bio2rdf.org/drugbank:DB01627'
p2860
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'LINCOMYCIN'
p2861
sg27
Nsg28
S'Antagonism between lincomycin and erythromycin in vitro has been demonstrated.| \r'
p2862
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERYTHROMYCIN'
p2863
sa(dp2864
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00887'
p2865
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p2866
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'LITHIUM CATION'
p2867
sg27
Nsg28
S'- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.| \r'
p2868
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BUMETANIDE'
p2869
sa(dp2870
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00482'
p2871
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p2872
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'LITHIUM CATION'
p2873
sg27
Nsg28
S'Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.| Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.| \r'
p2874
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Celebrex'
p2875
sa(dp2876
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p2877
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p2878
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'LITHIUM CATION'
p2879
sg27
Nsg28
S'Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.| \r'
p2880
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ESCITALOPRAM OXALATE'
p2881
sa(dp2882
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p2883
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p2884
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'LITHIUM CATION'
p2885
sg27
Nsg28
S'Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.| \r'
p2886
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ESCITALOPRAM'
p2887
sa(dp2888
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00502'
p2889
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p2890
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'LITHIUM CATION'
p2891
sg27
Nsg28
S'An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus HALDOL.| \r'
p2892
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Haldol'
p2893
sa(dp2894
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p2895
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p2896
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'LITHIUM CATION'
p2897
sg27
Nsg28
S'Inhibition of renal lithium clearance leading to increases in plasma lithium concentrations has also been reported.| Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.| \r'
p2898
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p2899
sa(dp2900
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p2901
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p2902
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'LITHIUM CATION'
p2903
sg27
Nsg28
S'Inhibition of renal lithium clearance leading to increases in plasma lithium concentrations has also been reported.| Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.| \r'
p2904
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p2905
sa(dp2906
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00887'
p2907
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p2908
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'LITHIUM'
p2909
sg27
Nsg28
S'- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.| \r'
p2910
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BUMETANIDE'
p2911
sa(dp2912
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00482'
p2913
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p2914
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'LITHIUM'
p2915
sg27
Nsg28
S'Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.| Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.| \r'
p2916
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Celebrex'
p2917
sa(dp2918
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p2919
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p2920
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'LITHIUM'
p2921
sg27
Nsg28
S'Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.| \r'
p2922
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ESCITALOPRAM OXALATE'
p2923
sa(dp2924
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p2925
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p2926
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'LITHIUM'
p2927
sg27
Nsg28
S'Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.| \r'
p2928
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ESCITALOPRAM'
p2929
sa(dp2930
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00502'
p2931
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p2932
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'LITHIUM'
p2933
sg27
Nsg28
S'An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus HALDOL.| \r'
p2934
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Haldol'
p2935
sa(dp2936
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p2937
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p2938
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'LITHIUM'
p2939
sg27
Nsg28
S'Inhibition of renal lithium clearance leading to increases in plasma lithium concentrations has also been reported.| Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.| \r'
p2940
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p2941
sa(dp2942
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p2943
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p2944
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'LITHIUM'
p2945
sg27
Nsg28
S'Inhibition of renal lithium clearance leading to increases in plasma lithium concentrations has also been reported.| Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.| \r'
p2946
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p2947
sa(dp2948
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p2949
sg5
S'http://bio2rdf.org/drugbank:DB00749'
p2950
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Lodine'
p2951
sg27
Nsg28
S'Aspirin When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.| however, as with other NSAIDs, concomitant administration of Lodine and aspirin is not generally recommended because of the potential of increased adverse effects.| \r'
p2952
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p2953
sa(dp2954
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p2955
sg5
S'http://bio2rdf.org/drugbank:DB00749'
p2956
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Lodine'
p2957
sg27
Nsg28
S'Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of furosemide and thiazides in some patients.| \r'
p2958
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FUROSEMIDE'
p2959
sa(dp2960
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p2961
sg5
S'http://bio2rdf.org/drugbank:DB00447'
p2962
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'LORACARBEF ANHYDROUS'
p2963
sg27
Nsg28
S'Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.| \r'
p2964
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROBENECID'
p2965
sa(dp2966
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p2967
sg5
S'http://bio2rdf.org/drugbank:DB00447'
p2968
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'LORACARBEF'
p2969
sg27
Nsg28
S'Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.| \r'
p2970
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROBENECID'
p2971
sa(dp2972
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p2973
sg5
S'http://bio2rdf.org/drugbank:DB00227'
p2974
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'LOVASTATIN'
p2975
sg27
Nsg28
S'Patients receiving concomitant lovastatin and erythromycin should be carefully monitored;| \r'
p2976
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERYTHROMYCIN'
p2977
sa(dp2978
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01155'
p2979
sg5
S'http://bio2rdf.org/drugbank:DB01378'
p2980
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'MAGNESIUM CATION'
p2981
sg27
Nsg28
S'Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| \r'
p2982
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Factive'
p2983
sa(dp2984
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01155'
p2985
sg5
S'http://bio2rdf.org/drugbank:DB01378'
p2986
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'MAGNESIUM'
p2987
sg27
Nsg28
S'Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| \r'
p2988
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Factive'
p2989
sa(dp2990
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00454'
p2991
sg5
S'http://bio2rdf.org/drugbank:DB00454'
p2992
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'MEPERIDINE'
p2993
sg27
Nsg28
S'Meperidine - Amphetamines pone the analgesic effect of meperidine.| \r'
p2994
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MEPERIDINE'
p2995
sa(dp2996
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p2997
sg5
S'http://bio2rdf.org/drugbank:DB00331'
p2998
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'METFORMIN'
p2999
sg27
Nsg28
S'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.| \r'
p3000
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOFETILIDE'
p3001
sa(dp3002
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p3003
sg5
S'http://bio2rdf.org/drugbank:DB00563'
p3004
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'METHOTREXATE'
p3005
sg27
Nsg28
S'Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.| \r'
p3006
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACETAMINOPHEN'
p3007
sa(dp3008
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00459'
p3009
sg5
S'http://bio2rdf.org/drugbank:DB00563'
p3010
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'METHOTREXATE'
p3011
sg27
Nsg28
S'Consequently, the combination of methotrexate with acitretin is also contraindicated.| \r'
p3012
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACITRETIN'
p3013
sa(dp3014
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00537'
p3015
sg5
S'http://bio2rdf.org/drugbank:DB00563'
p3016
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'METHOTREXATE'
p3017
sg27
Nsg28
S'Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate.| Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.| \r'
p3018
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIPROFLOXACIN'
p3019
sa(dp3020
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00926'
p3021
sg5
S'http://bio2rdf.org/drugbank:DB00563'
p3022
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'METHOTREXATE'
p3023
sg27
Nsg28
S'Methotrexate: An increased risk of hepatitis has been reported to result from combined use of methotrexate and etretinate.| \r'
p3024
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ETRETINATE'
p3025
sa(dp3026
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00041'
p3027
sg5
S'http://bio2rdf.org/drugbank:DB00563'
p3028
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'METHOTREXATE'
p3029
sg27
Nsg28
S'Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.| \r'
p3030
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Proleukin'
p3031
sa(dp3032
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00533'
p3033
sg5
S'http://bio2rdf.org/drugbank:DB00563'
p3034
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'METHOTREXATE'
p3035
sg27
Nsg28
S'At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).| \r'
p3036
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ROFECOXIB'
p3037
sa(dp3038
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00891'
p3039
sg5
S'http://bio2rdf.org/drugbank:DB00563'
p3040
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'METHOTREXATE'
p3041
sg27
Nsg28
S'- Methotrexate (e.g., Mexate)?Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate| \r'
p3042
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SULFAPYRIDINE'
p3043
sa(dp3044
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00891'
p3045
sg5
S'http://bio2rdf.org/drugbank:DB00968'
p3046
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'METHYLDOPA'
p3047
sg27
Nsg28
S'- Methyldopa (e.g., Aldomet)?Use of methyldopa with sulfapyridine may increase the chance of side effects affecting the liver and/or the blood| \r'
p3048
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SULFAPYRIDINE'
p3049
sa(dp3050
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p3051
sg5
S'http://bio2rdf.org/drugbank:DB00959'
p3052
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'METHYLPREDNISOLONE'
p3053
sg27
Nsg28
S'The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.| \r'
p3054
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'APREPITANT'
p3055
sa(dp3056
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00714'
p3057
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p3058
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'METOCLOPRAMIDE'
p3059
sg27
Nsg28
S'Dopamine Antagonists Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenoth-iazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.| \r'
p3060
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Apokyn'
p3061
sa(dp3062
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p3063
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p3064
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'METOCLOPRAMIDE'
p3065
sg27
Nsg28
S'Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.| \r'
p3066
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p3067
sa(dp3068
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01235'
p3069
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p3070
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'METOCLOPRAMIDE'
p3071
sg27
Nsg28
S'Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties.| \r'
p3072
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LEVODOPA'
p3073
sa(dp3074
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p3075
sg5
S'http://bio2rdf.org/drugbank:DB00683'
p3076
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'MIDAZOLAM'
p3077
sg27
Nsg28
S'The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.| \r'
p3078
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'APREPITANT'
p3079
sa(dp3080
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p3081
sg5
S'http://bio2rdf.org/drugbank:DB00683'
p3082
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'MIDAZOLAM'
p3083
sg27
Nsg28
S'The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.| \r'
p3084
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DILTIAZEM'
p3085
sa(dp3086
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p3087
sg5
S'http://bio2rdf.org/drugbank:DB00683'
p3088
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'MIDAZOLAM'
p3089
sg27
Nsg28
S'Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| \r'
p3090
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p3091
sa(dp3092
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00918'
p3093
sg5
S'http://bio2rdf.org/drugbank:DB01171'
p3094
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'MOCLOBEMIDE'
p3095
sg27
Nsg28
S'Monoamine Oxidase Inhibitors Coadministration of moclobemide resulted in a 27% decrease in almotriptan clearance and an increase in Cmax of approximately 6%.| \r'
p3096
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALMOTRIPTAN'
p3097
sa(dp3098
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00828'
p3099
sg5
S'http://bio2rdf.org/drugbank:DB00828'
p3100
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Monurol'
p3101
sg27
Nsg28
S'Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.| \r'
p3102
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FOSFOMYCIN'
p3103
sa(dp3104
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p3105
sg5
S'http://bio2rdf.org/drugbank:DB00486'
p3106
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Nabilone'
p3107
sg27
Nsg28
S'Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.| Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).| \r'
p3108
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p3109
sa(dp3110
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p3111
sg5
S'http://bio2rdf.org/drugbank:DB00486'
p3112
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Nabilone'
p3113
sg27
Nsg28
S'Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.| \r'
p3114
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIAZEPAM'
p3115
sa(dp3116
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00659'
p3117
sg5
S'http://bio2rdf.org/drugbank:DB00704'
p3118
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'NALTREXONE'
p3119
sg27
Nsg28
S'Co-administration of naltrexone with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.| \r'
p3120
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACAMPROSATE'
p3121
sa(dp3122
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3123
sg5
S'http://bio2rdf.org/drugbank:DB00788'
p3124
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'NAPROXEN'
p3125
sg27
Nsg28
S'Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.| \r'
p3126
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p3127
sa(dp3128
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p3129
sg5
S'http://bio2rdf.org/drugbank:DB00788'
p3130
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'NAPROXEN'
p3131
sg27
Nsg28
S'Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.| \r'
p3132
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHOTREXATE'
p3133
sa(dp3134
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p3135
sg5
S'http://bio2rdf.org/drugbank:DB01149'
p3136
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'NEFAZODONE'
p3137
sg27
Nsg28
S'Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| \r'
p3138
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p3139
sa(dp3140
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00701'
p3141
sg5
S'http://bio2rdf.org/drugbank:DB05251'
p3142
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'NELFINAVIR'
p3143
sg27
Nsg28
S'Nelfinavir steady-state Cmax, A.C. and Cmin were increased by 12%, 15%, and 14%, respectively, by concomitant amprenavir.| \r'
p3144
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPRENAVIR'
p3145
sa(dp3146
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00903'
p3147
sg5
S'http://bio2rdf.org/drugbank:DB00955'
p3148
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'NETILMICIN'
p3149
sg27
Nsg28
S'Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.| \r'
p3150
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ETHACRYNIC ACID'
p3151
sa(dp3152
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p3153
sg5
S'http://bio2rdf.org/drugbank:DB00238'
p3154
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'NEVIRAPINE'
p3155
sg27
Nsg28
S'Nevirapine and ketoconazole should not beadministered concomitantly becausedecreases in ketoconazole plasmaconcentrations may reduce the efficacy of the drug.| \r'
p3156
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p3157
sa(dp3158
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p3159
sg5
S'http://bio2rdf.org/drugbank:DB00238'
p3160
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'NEVIRAPINE'
p3161
sg27
Nsg28
S'Nevirapine and rifampin should not beadministered concomitantly becausedecreases in nevirapine plasmaconcentrations may reduce the efficacy ofthe drug.| \r'
p3162
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RIFAMPIN'
p3163
sa(dp3164
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00202'
p3165
sg5
S'http://bio2rdf.org/drugbank:DB00565'
p3166
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Nimbex'
p3167
sg27
Nsg28
S'Administration of 0.1-mg/kg (2 x ED95) NIMBEX at 10% or 95% recovery following an intubating dose of succinylcholine (1 mg/kg) produced ?95% neuromuscular block.| \r'
p3168
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUCCINYLCHOLINE'
p3169
sa(dp3170
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01197'
p3171
sg5
S'http://bio2rdf.org/drugbank:DB00727'
p3172
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'NITROGLYCERIN'
p3173
sg27
Nsg28
S'therefore, nitroglycerin or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting captopril.| \r'
p3174
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CAPTOPRIL'
p3175
sa(dp3176
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00435'
p3177
sg5
S'http://bio2rdf.org/drugbank:DB00727'
p3178
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'NITROGLYCERIN'
p3179
sg27
Nsg28
S'Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.| \r'
p3180
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INOmax'
p3181
sa(dp3182
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00368'
p3183
sg5
S'http://bio2rdf.org/drugbank:DB00368'
p3184
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'NOREPINEPHRINE'
p3185
sg27
Nsg28
S'Norepinephrine - Amphetamines enhance the adrenergic effect of norepinephrine.| \r'
p3186
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NOREPINEPHRINE'
p3187
sa(dp3188
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00996'
p3189
sg5
S'http://bio2rdf.org/drugbank:DB00717'
p3190
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'NORETHINDRONE'
p3191
sg27
Nsg28
S'The Cmax of norethindrone was 13% higher when it was coadministered with gabapentin;| \r'
p3192
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GABAPENTIN'
p3193
sa(dp3194
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p3195
sg5
S'http://bio2rdf.org/drugbank:DB01059'
p3196
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'NORFLOXACIN'
p3197
sg27
Nsg28
S'There have been reports of theophylline-related side effects in patients on concomitant therapy with norfloxacin and theophylline.| \r'
p3198
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p3199
sa(dp3200
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p3201
sg5
S'http://bio2rdf.org/drugbank:DB01059'
p3202
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'NORFLOXACIN'
p3203
sg27
Nsg28
S'Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| \r'
p3204
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tikosyn'
p3205
sa(dp3206
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p3207
sg5
S'http://bio2rdf.org/drugbank:DB00280'
p3208
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Norpace'
p3209
sg27
Nsg28
S'Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.| \r'
p3210
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'QUINIDINE'
p3211
sa(dp3212
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3213
sg5
S'http://bio2rdf.org/drugbank:DB03585'
p3214
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Oxyphenbutazone'
p3215
sg27
Nsg28
S'Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.| \r'
p3216
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p3217
sa(dp3218
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00289'
p3219
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p3220
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PAROXETINE'
p3221
sg27
Nsg28
S'In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.| \r'
p3222
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ATOMOXETINE'
p3223
sa(dp3224
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00363'
p3225
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p3226
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PAROXETINE'
p3227
sg27
Nsg28
S'Paroxetine produced only minor changes in the levels of clozapine and its metabolites.| \r'
p3228
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLOZAPINE'
p3229
sa(dp3230
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00476'
p3231
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p3232
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PAROXETINE'
p3233
sg27
Nsg28
S'Paroxetine (20 mg QD) increased the concentration of duloxetine (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.| \r'
p3234
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DULOXETINE'
p3235
sa(dp3236
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01121'
p3237
sg5
S'http://bio2rdf.org/drugbank:DB00754'
p3238
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Peganone'
p3239
sg27
Nsg28
S'Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.| \r'
p3240
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENACEMIDE'
p3241
sa(dp3242
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01121'
p3243
sg5
S'http://bio2rdf.org/drugbank:DB00754'
p3244
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Peganone'
p3245
sg27
Nsg28
S'Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.| \r'
p3246
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Phenurone'
p3247
sa(dp3248
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p3249
sg5
S'http://bio2rdf.org/drugbank:DB00008'
p3250
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Pegasys'
p3251
sg27
Nsg28
S'Treatment with PEGASYS once weekly for 4 weeks in healthy subjects was associated with an inhibition of P450 1A2 and a 25% increase in theophylline AUC.| \r'
p3252
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p3253
sa(dp3254
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00854'
p3255
sg5
S'http://bio2rdf.org/drugbank:DB00652'
p3256
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PENTAZOCINE, (-)-'
p3257
sg27
Nsg28
S'Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| \r'
p3258
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Levo-Dromoran'
p3259
sa(dp3260
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3261
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3262
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p3263
sg27
Nsg28
S'Phenobarbital: Decreases aspirin effectiveness by enzyme induction.| \r'
p3264
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p3265
sa(dp3266
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p3267
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3268
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p3269
sg27
Nsg28
S'Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.| \r'
p3270
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BEXAROTENE'
p3271
sa(dp3272
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00136'
p3273
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3274
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p3275
sg27
Nsg28
S'Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.| \r'
p3276
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CALCITRIOL'
p3277
sa(dp3278
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01068'
p3279
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3280
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p3281
sg27
Nsg28
S'Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.| \r'
p3282
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLONAZEPAM'
p3283
sa(dp3284
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00990'
p3285
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3286
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p3287
sg27
Nsg28
S'Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John?s wort) may significantly decrease exposure to exemestane.| \r'
p3288
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EXEMESTANE'
p3289
sa(dp3290
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00949'
p3291
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3292
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p3293
sg27
Nsg28
S'Phenobarbital: It appears that phenobarbital may reduce plasma felbamate concentrations.| \r'
p3294
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FELBAMATE'
p3295
sa(dp3296
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00573'
p3297
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3298
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p3299
sg27
Nsg28
S'Chronic administration of phenobarbital, a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen.| \r'
p3300
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Fenoprofen'
p3301
sa(dp3302
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00573'
p3303
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3304
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p3305
sg27
Nsg28
S'When phenobarbital is added to or withdrawn from treatment, dosage adjustment of Nalfon may be required.| \r'
p3306
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nalfon'
p3307
sa(dp3308
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p3309
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3310
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p3311
sg27
Nsg28
S'Phenobarbital - Amphetamines may delay intestinal absorption of phenobarbital;| \r'
p3312
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p3313
sa(dp3314
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p3315
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3316
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p3317
sg27
Nsg28
S'Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| \r'
p3318
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p3319
sa(dp3320
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p3321
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3322
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p3323
sg27
Nsg28
S'Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| \r'
p3324
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p3325
sa(dp3326
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3327
sg5
S'http://bio2rdf.org/drugbank:DB00812'
p3328
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENYLBUTAZONE'
p3329
sg27
Nsg28
S'Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.| \r'
p3330
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p3331
sa(dp3332
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00749'
p3333
sg5
S'http://bio2rdf.org/drugbank:DB00812'
p3334
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENYLBUTAZONE'
p3335
sg27
Nsg28
S'Phenylbutazone Phenylbutazone causes increase (by about 80%) in the free fraction of etodolac.| \r'
p3336
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Etodolac'
p3337
sa(dp3338
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p3339
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p3340
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENYTOIN'
p3341
sg27
Nsg28
S'Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.| \r'
p3342
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BEXAROTENE'
p3343
sa(dp3344
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01008'
p3345
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p3346
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENYTOIN'
p3347
sg27
Nsg28
S'Phenytoin increases the clearance of busulfan by 15% or more, possibly due to the induction of glutathione-S-transferase.| \r'
p3348
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BUSULFAN'
p3349
sa(dp3350
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00136'
p3351
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p3352
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENYTOIN'
p3353
sg27
Nsg28
S'Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.| \r'
p3354
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CALCITRIOL'
p3355
sa(dp3356
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00537'
p3357
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p3358
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENYTOIN'
p3359
sg27
Nsg28
S'Phenytoin Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin.| \r'
p3360
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIPROFLOXACIN'
p3361
sa(dp3362
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01068'
p3363
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p3364
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENYTOIN'
p3365
sg27
Nsg28
S'Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.| \r'
p3366
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLONAZEPAM'
p3367
sa(dp3368
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00254'
p3369
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p3370
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENYTOIN'
p3371
sg27
Nsg28
S'Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.| \r'
p3372
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOXYCYCLINE'
p3373
sa(dp3374
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01215'
p3375
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p3376
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENYTOIN'
p3377
sg27
Nsg28
S'While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.| \r'
p3378
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ESTAZOLAM'
p3379
sa(dp3380
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00990'
p3381
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p3382
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENYTOIN'
p3383
sg27
Nsg28
S'Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John?s wort) may significantly decrease exposure to exemestane.| \r'
p3384
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EXEMESTANE'
p3385
sa(dp3386
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00949'
p3387
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p3388
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENYTOIN'
p3389
sg27
Nsg28
S'Effects of Other Antiepileptic Drugs on Felbatol? Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol? (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol? as compared to the same dose of Felbatol? given as monotherapy.| \r'
p3390
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FELBAMATE'
p3391
sa(dp3392
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00544'
p3393
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p3394
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENYTOIN'
p3395
sg27
Nsg28
S'Concomitant administration of phenytoin and ERGAMISOL? plus fluorouracil has lead to increased plasma levels of phenytoin.| \r'
p3396
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUOROURACIL'
p3397
sa(dp3398
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00280'
p3399
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p3400
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENYTOIN'
p3401
sg27
Nsg28
S'If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of disopyramide may occur.| \r'
p3402
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Norpace'
p3403
sa(dp3404
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p3405
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p3406
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENYTOIN'
p3407
sg27
Nsg28
S'Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| \r'
p3408
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p3409
sa(dp3410
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p3411
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p3412
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENYTOIN'
p3413
sg27
Nsg28
S'Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| \r'
p3414
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p3415
sa(dp3416
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00891'
p3417
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p3418
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENYTOIN'
p3419
sg27
Nsg28
S'- Phenytoin (e.g., Dilantin)?Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin| \r'
p3420
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SULFAPYRIDINE'
p3421
sa(dp3422
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00202'
p3423
sg5
S'http://bio2rdf.org/drugbank:DB01057'
p3424
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Phospholine Iodide'
p3425
sg27
Nsg28
S'Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides.| \r'
p3426
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUCCINYLCHOLINE'
p3427
sa(dp3428
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p3429
sg5
S'http://bio2rdf.org/drugbank:DB01100'
p3430
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PIMOZIDE'
p3431
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p3432
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p3433
sa(dp3434
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p3435
sg5
S'http://bio2rdf.org/drugbank:DB01100'
p3436
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PIMOZIDE'
p3437
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p3438
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p3439
sa(dp3440
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p3441
sg5
S'http://bio2rdf.org/drugbank:DB01166'
p3442
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Pletal'
p3443
sg27
Nsg28
S'Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.| \r'
p3444
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p3445
sa(dp3446
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3447
sg5
S'http://bio2rdf.org/drugbank:DB00784'
p3448
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ponstel'
p3449
sg27
Nsg28
S'Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.| \r'
p3450
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASPIRIN'
p3451
sa(dp3452
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p3453
sg5
S'http://bio2rdf.org/drugbank:DB00784'
p3454
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ponstel'
p3455
sg27
Nsg28
S'During concomitant therapy of Ponstel with furosemide, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.| \r'
p3456
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FUROSEMIDE'
p3457
sa(dp3458
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00584'
p3459
sg5
S'http://bio2rdf.org/drugbank:DB01345'
p3460
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'POTASSIUM'
p3461
sg27
Nsg28
S'Potassium sparing agents should generally not be used in patients with heart failure receiving enalapril.| \r'
p3462
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ENALAPRIL'
p3463
sa(dp3464
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00722'
p3465
sg5
S'http://bio2rdf.org/drugbank:DB01345'
p3466
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'POTASSIUM'
p3467
sg27
Nsg28
S'Potassium sparing agents should generally not be used in patients with heart failure who are receiving PRINIVIL.| \r'
p3468
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Prinivil'
p3469
sa(dp3470
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p3471
sg5
S'http://bio2rdf.org/drugbank:DB00722'
p3472
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Prinivil'
p3473
sg27
Nsg28
S'It is recommended that serum lithium levels be monitored frequently if PRINIVIL is administered concomitantly with lithium.| \r'
p3474
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p3475
sa(dp3476
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p3477
sg5
S'http://bio2rdf.org/drugbank:DB00722'
p3478
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Prinivil'
p3479
sg27
Nsg28
S'It is recommended that serum lithium levels be monitored frequently if PRINIVIL is administered concomitantly with lithium.| \r'
p3480
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p3481
sa(dp3482
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00384'
p3483
sg5
S'http://bio2rdf.org/drugbank:DB00722'
p3484
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Prinivil'
p3485
sg27
Nsg28
S'Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.| \r'
p3486
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TRIAMTERENE'
p3487
sa(dp3488
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p3489
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3490
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PROBENECID'
p3491
sg27
Nsg28
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p3492
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACETAMINOPHEN'
p3493
sa(dp3494
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00787'
p3495
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3496
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PROBENECID'
p3497
sg27
Nsg28
S'Co-administration of probenecid with acyclovir has been shown to increase the mean half-life and the area under the concentration-time curve.| Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p3498
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACYCLOVIR'
p3499
sa(dp3500
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p3501
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3502
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PROBENECID'
p3503
sg27
Nsg28
S'Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.| \r'
p3504
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ADENOSINE PHOSPHATE'
p3505
sa(dp3506
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00233'
p3507
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3508
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PROBENECID'
p3509
sg27
Nsg28
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p3510
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMINOSALICYLIC ACID'
p3511
sa(dp3512
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p3513
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3514
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PROBENECID'
p3515
sg27
Nsg28
S'Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.| \r'
p3516
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPICILLIN'
p3517
sa(dp3518
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00887'
p3519
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3520
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PROBENECID'
p3521
sg27
Nsg28
S'- Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.| Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| This antagonistic effect of probenecid on bu-metanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.| Thus, probenecid should not be administered concurrently with bumetanide.| \r'
p3522
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BUMETANIDE'
p3523
sa(dp3524
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00535'
p3525
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3526
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PROBENECID'
p3527
sg27
Nsg28
S'Probenecid As with other b span class= c233 -lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.| \r'
p3528
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CEFDINIR'
p3529
sa(dp3530
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00537'
p3531
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3532
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PROBENECID'
p3533
sg27
Nsg28
S'Probenecid Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.| \r'
p3534
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIPROFLOXACIN'
p3535
sa(dp3536
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00636'
p3537
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3538
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PROBENECID'
p3539
sg27
Nsg28
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p3540
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLOFIBRATE'
p3541
sa(dp3542
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00927'
p3543
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3544
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PROBENECID'
p3545
sg27
Nsg28
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p3546
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FAMOTIDINE'
p3547
sa(dp3548
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p3549
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3550
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PROBENECID'
p3551
sg27
Nsg28
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p3552
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FUROSEMIDE'
p3553
sa(dp3554
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p3555
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3556
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PROBENECID'
p3557
sg27
Nsg28
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p3558
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHOTREXATE'
p3559
sa(dp3560
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00788'
p3561
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3562
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PROBENECID'
p3563
sg27
Nsg28
S'Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly.| \r'
p3564
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NAPROXEN'
p3565
sa(dp3566
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01059'
p3567
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3568
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PROBENECID'
p3569
sg27
Nsg28
S'Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of probenecid and norfloxacin.| \r'
p3570
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NORFLOXACIN'
p3571
sa(dp3572
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00299'
p3573
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3574
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PROBENECID'
p3575
sg27
Nsg28
S'Concurrent use with probenecid or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of penciclovir.| \r'
p3576
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PENCICLOVIR'
p3577
sa(dp3578
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p3579
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3580
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PROBENECID'
p3581
sg27
Nsg28
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p3582
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p3583
sa(dp3584
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00495'
p3585
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3586
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PROBENECID'
p3587
sg27
Nsg28
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p3588
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZIDOVUDINE'
p3589
sa(dp3590
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p3591
sg5
S'http://bio2rdf.org/drugbank:DB00782'
p3592
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PROPANTHELINE'
p3593
sg27
Nsg28
S'Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.| \r'
p3594
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p3595
sa(dp3596
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p3597
sg5
S'http://bio2rdf.org/drugbank:DB00647'
p3598
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PROPOXYPHENE'
p3599
sg27
Nsg28
S'Propoxyphene: Coadministration of propoxyphene decreased the maximum plasma concentration of alprazolam by 6%, decreased clearance by 38%, and increased half-life by 58%.| \r'
p3600
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALPRAZOLAM'
p3601
sa(dp3602
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01575'
p3603
sg5
S'http://bio2rdf.org/drugbank:DB00852'
p3604
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PSEUDOEPHEDRINE'
p3605
sg27
Nsg28
S'Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it.| \r'
p3606
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'KAOLIN'
p3607
sa(dp3608
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00488'
p3609
sg5
S'http://bio2rdf.org/drugbank:DB00165'
p3610
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PYRIDOXINE'
p3611
sg27
Nsg28
S'however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN and/or cisplatin.1| \r'
p3612
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Hexalen'
p3613
sa(dp3614
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01238'
p3615
sg5
S'http://bio2rdf.org/drugbank:DB00908'
p3616
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'QUINIDINE'
p3617
sg27
Nsg28
S'Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs.| \r'
p3618
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ARIPIPRAZOLE'
p3619
sa(dp3620
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p3621
sg5
S'http://bio2rdf.org/drugbank:DB00908'
p3622
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'QUINIDINE'
p3623
sg27
Nsg28
S'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| \r'
p3624
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p3625
sa(dp3626
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p3627
sg5
S'http://bio2rdf.org/drugbank:DB00908'
p3628
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'QUINIDINE'
p3629
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p3630
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p3631
sa(dp3632
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p3633
sg5
S'http://bio2rdf.org/drugbank:DB00908'
p3634
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'QUINIDINE'
p3635
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p3636
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p3637
sa(dp3638
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p3639
sg5
S'http://bio2rdf.org/drugbank:DB00468'
p3640
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'QUININE'
p3641
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p3642
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p3643
sa(dp3644
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p3645
sg5
S'http://bio2rdf.org/drugbank:DB00468'
p3646
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'QUININE'
p3647
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p3648
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p3649
sa(dp3650
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p3651
sg5
S'http://bio2rdf.org/drugbank:DB00468'
p3652
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'QUININE'
p3653
sg27
Nsg28
S'Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| \r'
p3654
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tikosyn'
p3655
sa(dp3656
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00630'
p3657
sg5
S'http://bio2rdf.org/drugbank:DB00863'
p3658
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'RANITIDINE'
p3659
sg27
Nsg28
S'Intravenous ranitidine was shown to double the bioavailability of oral alendronate.| \r'
p3660
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALENDRONIC ACID'
p3661
sa(dp3662
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01415'
p3663
sg5
S'http://bio2rdf.org/drugbank:DB00863'
p3664
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'RANITIDINE'
p3665
sg27
Nsg28
S'however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.| \r'
p3666
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CEFTIBUTEN'
p3667
sa(dp3668
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p3669
sg5
S'http://bio2rdf.org/drugbank:DB00863'
p3670
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'RANITIDINE'
p3671
sg27
Nsg28
S'The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.| \r'
p3672
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p3673
sa(dp3674
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00612'
p3675
sg5
S'http://bio2rdf.org/drugbank:DB00206'
p3676
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'RESERPINE'
p3677
sg27
Nsg28
S'Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.| \r'
p3678
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Zebeta'
p3679
sa(dp3680
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00459'
p3681
sg5
S'http://bio2rdf.org/drugbank:DB00162'
p3682
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'RETINOL'
p3683
sg27
Nsg28
S'Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.| \r'
p3684
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACITRETIN'
p3685
sa(dp3686
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00822'
p3687
sg5
S'http://bio2rdf.org/drugbank:DB00704'
p3688
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Revia'
p3689
sg27
Nsg28
S'The safety and efficacy of concomitant use of REVIA and disulfiram is unknown, and the concomitant use of two potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known risks.| \r'
p3690
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DISULFIRAM'
p3691
sa(dp3692
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p3693
sg5
S'http://bio2rdf.org/drugbank:DB00615'
p3694
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'RIFABUTIN'
p3695
sg27
Nsg28
S'Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.| \r'
p3696
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Crixivan'
p3697
sa(dp3698
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p3699
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p3700
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'RIFAMPIN'
p3701
sg27
Nsg28
S'Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.| \r'
p3702
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BEXAROTENE'
p3703
sa(dp3704
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p3705
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p3706
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'RIFAMPIN'
p3707
sg27
Nsg28
S'Rifampin may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin.| \r'
p3708
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p3709
sa(dp3710
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p3711
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p3712
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'RIFAMPIN'
p3713
sg27
Nsg28
S'Coadministration of rifampin with diltiazem lowered the diltiazem plasma concentrations to undetectable levels.| \r'
p3714
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DILTIAZEM'
p3715
sa(dp3716
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01215'
p3717
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p3718
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'RIFAMPIN'
p3719
sg27
Nsg28
S'While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.| \r'
p3720
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ESTAZOLAM'
p3721
sa(dp3722
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00990'
p3723
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p3724
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'RIFAMPIN'
p3725
sg27
Nsg28
S'Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John?s wort) may significantly decrease exposure to exemestane.| \r'
p3726
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EXEMESTANE'
p3727
sa(dp3728
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00619'
p3729
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p3730
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'RIFAMPIN'
p3731
sg27
Nsg28
S'Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).| \r'
p3732
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Gleevec'
p3733
sa(dp3734
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00502'
p3735
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p3736
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'RIFAMPIN'
p3737
sg27
Nsg28
S'Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.| \r'
p3738
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HALOPERIDOL'
p3739
sa(dp3740
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p3741
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p3742
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'RIFAMPIN'
p3743
sg27
Nsg28
S'Concomitant administration of rifampin with ketoconazole tablets reduces the blood levels of the latter.| \r'
p3744
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p3745
sa(dp3746
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p3747
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p3748
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'RIFAMPIN'
p3749
sg27
Nsg28
S'Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir.| \r'
p3750
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p3751
sa(dp3752
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p3753
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p3754
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'RIFAMPIN'
p3755
sg27
Nsg28
S'Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir.| \r'
p3756
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p3757
sa(dp3758
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00612'
p3759
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p3760
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'RIFAMPIN'
p3761
sg27
Nsg28
S'Concurrent use of rifampin increases the metabolic clearance of ZEBETA, resulting in a shortened elimination half-life of ZEBETA.| \r'
p3762
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Zebeta'
p3763
sa(dp3764
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01198'
p3765
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p3766
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'RIFAMPIN'
p3767
sg27
Nsg28
S'Drugs That Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant useof rifampicin, a potent inducer of CYP3A4.| \r'
p3768
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Zopiclone'
p3769
sa(dp3770
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01235'
p3771
sg5
S'http://bio2rdf.org/drugbank:DB00734'
p3772
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'RISPERIDONE'
p3773
sg27
Nsg28
S'Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.| \r'
p3774
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LEVODOPA'
p3775
sa(dp3776
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p3777
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p3778
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'RITONAVIR'
p3779
sg27
Nsg28
S'Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| \r'
p3780
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p3781
sa(dp3782
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00529'
p3783
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p3784
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'RITONAVIR'
p3785
sg27
Nsg28
S'Abnormal renal function has been observed in clinical practice during the use of FASCAVIR and ritonavir, or FOSCAVIR, ritonavir, and saquinavir.| \r'
p3786
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Foscavir'
p3787
sa(dp3788
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00761'
p3789
sg5
S'http://bio2rdf.org/drugbank:DB00986'
p3790
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Robinul'
p3791
sg27
Nsg28
S'Concomitant administration of Robinul Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.| \r'
p3792
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'POTASSIUM CHLORIDE'
p3793
sa(dp3794
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00701'
p3795
sg5
S'http://bio2rdf.org/drugbank:DB01232'
p3796
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'SAQUINAVIR MESYLATE'
p3797
sg27
Nsg28
S'Saquinavir steady-state Cmax, A.C. and Cmin were increased 21%, decreased 19%, and decreased 48%, respectively, by concomitant amprenavir.| \r'
p3798
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPRENAVIR'
p3799
sa(dp3800
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00701'
p3801
sg5
S'http://bio2rdf.org/drugbank:DB01232'
p3802
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'SAQUINAVIR'
p3803
sg27
Nsg28
S'Saquinavir steady-state Cmax, A.C. and Cmin were increased 21%, decreased 19%, and decreased 48%, respectively, by concomitant amprenavir.| \r'
p3804
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPRENAVIR'
p3805
sa(dp3806
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p3807
sg5
S'http://bio2rdf.org/drugbank:DB00203'
p3808
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'SILDENAFIL'
p3809
sg27
Nsg28
S'Sildenafil dose should not exceed a maximum of 25 mg in a 48- hour period in patients receiving concomitant indinavir therapy.| \r'
p3810
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDINAVIR ANHYDROUS'
p3811
sa(dp3812
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p3813
sg5
S'http://bio2rdf.org/drugbank:DB00203'
p3814
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'SILDENAFIL'
p3815
sg27
Nsg28
S'Sildenafil dose should not exceed a maximum of 25 mg in a 48- hour period in patients receiving concomitant indinavir therapy.| \r'
p3816
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDINAVIR'
p3817
sa(dp3818
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p3819
sg5
S'http://bio2rdf.org/drugbank:DB00962'
p3820
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Sonata'
p3821
sg27
Nsg28
S'CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.| \r'
p3822
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALCOHOL'
p3823
sa(dp3824
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p3825
sg5
S'http://bio2rdf.org/drugbank:DB00962'
p3826
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Sonata'
p3827
sg27
Nsg28
S'Concomitant administration of Sonata (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon.| \r'
p3828
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIMETIDINE'
p3829
sa(dp3830
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00962'
p3831
sg5
S'http://bio2rdf.org/drugbank:DB00962'
p3832
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Sonata'
p3833
sg27
Nsg28
S'Concomitant administration of Sonata (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon.| \r'
p3834
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZALEPLON'
p3835
sa(dp3836
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p3837
sg5
S'http://bio2rdf.org/drugbank:DB00421'
p3838
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'SPIRONOLACTONE'
p3839
sg27
Nsg28
S'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| \r'
p3840
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p3841
sa(dp3842
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00187'
p3843
sg5
S'http://bio2rdf.org/drugbank:DB00202'
p3844
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'SUCCINYLCHOLINE'
p3845
sg27
Nsg28
S'The onset of neuromuscular blockade by succinylcholine was unaffected by BREVIBLOC, but the duration of neuromuscular blockade was prolonged from 5 minutes to 8 minutes.| \r'
p3846
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Brevibloc'
p3847
sa(dp3848
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p3849
sg5
S'http://bio2rdf.org/drugbank:DB00795'
p3850
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'SULFASALAZINE'
p3851
sg27
Nsg28
S'Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.| \r'
p3852
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p3853
sa(dp3854
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p3855
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p3856
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'SUMATRIPTAN SUCCINATE'
p3857
sg27
Nsg28
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p3858
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ESCITALOPRAM OXALATE'
p3859
sa(dp3860
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p3861
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p3862
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'SUMATRIPTAN SUCCINATE'
p3863
sg27
Nsg28
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p3864
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ESCITALOPRAM'
p3865
sa(dp3866
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p3867
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p3868
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'SUMATRIPTAN SUCCINATE'
p3869
sg27
Nsg28
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p3870
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p3871
sa(dp3872
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p3873
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p3874
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'SUMATRIPTAN SUCCINATE'
p3875
sg27
Nsg28
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p3876
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PAROXETINE'
p3877
sa(dp3878
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01104'
p3879
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p3880
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'SUMATRIPTAN SUCCINATE'
p3881
sg27
Nsg28
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p3882
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SERTRALINE'
p3883
sa(dp3884
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p3885
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p3886
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'SUMATRIPTAN'
p3887
sg27
Nsg28
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p3888
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ESCITALOPRAM OXALATE'
p3889
sa(dp3890
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p3891
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p3892
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'SUMATRIPTAN'
p3893
sg27
Nsg28
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p3894
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ESCITALOPRAM'
p3895
sa(dp3896
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p3897
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p3898
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'SUMATRIPTAN'
p3899
sg27
Nsg28
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p3900
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p3901
sa(dp3902
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p3903
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p3904
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'SUMATRIPTAN'
p3905
sg27
Nsg28
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p3906
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PAROXETINE'
p3907
sa(dp3908
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01104'
p3909
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p3910
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'SUMATRIPTAN'
p3911
sg27
Nsg28
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p3912
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SERTRALINE'
p3913
sa(dp3914
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00559'
p3915
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p3916
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TACROLIMUS ANHYDROUS'
p3917
sg27
Nsg28
S'Caution should be exercised if tacrolimus and bosentan are used together.| Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.| \r'
p3918
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BOSENTAN ANHYDROUS'
p3919
sa(dp3920
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00559'
p3921
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p3922
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TACROLIMUS ANHYDROUS'
p3923
sg27
Nsg28
S'Caution should be exercised if tacrolimus and bosentan are used together.| Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.| \r'
p3924
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BOSENTAN'
p3925
sa(dp3926
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p3927
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p3928
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TACROLIMUS ANHYDROUS'
p3929
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p3930
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p3931
sa(dp3932
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p3933
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p3934
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TACROLIMUS ANHYDROUS'
p3935
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p3936
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p3937
sa(dp3938
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00559'
p3939
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p3940
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TACROLIMUS'
p3941
sg27
Nsg28
S'Caution should be exercised if tacrolimus and bosentan are used together.| Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.| \r'
p3942
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BOSENTAN ANHYDROUS'
p3943
sa(dp3944
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00559'
p3945
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p3946
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TACROLIMUS'
p3947
sg27
Nsg28
S'Caution should be exercised if tacrolimus and bosentan are used together.| Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.| \r'
p3948
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BOSENTAN'
p3949
sa(dp3950
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p3951
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p3952
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TACROLIMUS'
p3953
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p3954
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p3955
sa(dp3956
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p3957
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p3958
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TACROLIMUS'
p3959
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p3960
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p3961
sa(dp3962
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p3963
sg5
S'http://bio2rdf.org/drugbank:DB00820'
p3964
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TADALAFIL'
p3965
sg27
Nsg28
S'Tadalafil dose should not exceed a maximum of 10 mg in a 72- hour period in patients receiving concomitant indinavir therapy.| \r'
p3966
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDINAVIR ANHYDROUS'
p3967
sa(dp3968
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p3969
sg5
S'http://bio2rdf.org/drugbank:DB00820'
p3970
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TADALAFIL'
p3971
sg27
Nsg28
S'Tadalafil dose should not exceed a maximum of 10 mg in a 72- hour period in patients receiving concomitant indinavir therapy.| \r'
p3972
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDINAVIR'
p3973
sa(dp3974
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00475'
p3975
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p3976
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Tagamet'
p3977
sg27
Nsg28
S'Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| \r'
p3978
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CHLORDIAZEPOXIDE'
p3979
sa(dp3980
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p3981
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p3982
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Tagamet'
p3983
sg27
Nsg28
S'Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| \r'
p3984
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIAZEPAM'
p3985
sa(dp3986
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB05291'
p3987
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p3988
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Tagamet'
p3989
sg27
Nsg28
S'Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| \r'
p3990
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LIDOCAINE'
p3991
sa(dp3992
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00916'
p3993
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p3994
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Tagamet'
p3995
sg27
Nsg28
S'Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| \r'
p3996
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METRONIDAZOLE'
p3997
sa(dp3998
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01115'
p3999
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p4000
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Tagamet'
p4001
sg27
Nsg28
S'Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| \r'
p4002
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NIFEDIPINE'
p4003
sa(dp4004
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p4005
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p4006
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Tagamet'
p4007
sg27
Nsg28
S'Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| \r'
p4008
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p4009
sa(dp4010
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p4011
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p4012
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Tagamet'
p4013
sg27
Nsg28
S'Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| \r'
p4014
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p4015
sa(dp4016
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p4017
sg5
S'http://bio2rdf.org/drugbank:DB01195'
p4018
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Tambocor'
p4019
sg27
Nsg28
S'During administration of multiple oral doses of TAMBOCOR to healthy subjects stabilized on a maintenance dose of digoxin, a 13%-19% increase in plasma digoxin levels occurred at six hours postdose.| \r'
p4020
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p4021
sa(dp4022
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01217'
p4023
sg5
S'http://bio2rdf.org/drugbank:DB00675'
p4024
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TAMOXIFEN'
p4025
sg27
Nsg28
S'Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole (see CLINICAL PHARMACOLOGY ? Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).| \r'
p4026
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ANASTROZOLE'
p4027
sa(dp4028
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p4029
sg5
S'http://bio2rdf.org/drugbank:DB00307'
p4030
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Targretin'
p4031
sg27
Nsg28
S'Concomitant administration of Targretin ? capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.| \r'
p4032
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BEXAROTENE'
p4033
sa(dp4034
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01241'
p4035
sg5
S'http://bio2rdf.org/drugbank:DB00307'
p4036
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Targretin'
p4037
sg27
Nsg28
S'Concomitant administration of Targretin ? capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.| \r'
p4038
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GEMFIBROZIL'
p4039
sa(dp4040
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01294'
p4041
sg5
S'http://bio2rdf.org/drugbank:DB00759'
p4042
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TETRACYCLINE'
p4043
sg27
Nsg28
S'Absorption of tetracycline is impaired by bismuth subsalicylate.| \r'
p4044
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BISMUTH SUBSALICYLATE'
p4045
sa(dp4046
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p4047
sg5
S'http://bio2rdf.org/drugbank:DB00759'
p4048
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TETRACYCLINE'
p4049
sg27
Nsg28
S'Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.| \r'
p4050
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p4051
sa(dp4052
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01028'
p4053
sg5
S'http://bio2rdf.org/drugbank:DB00759'
p4054
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TETRACYCLINE'
p4055
sg27
Nsg28
S'The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.| \r'
p4056
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHOXYFLURANE'
p4057
sa(dp4058
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01028'
p4059
sg5
S'http://bio2rdf.org/drugbank:DB00759'
p4060
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TETRACYCLINE'
p4061
sg27
Nsg28
S'The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.| \r'
p4062
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Penthrane'
p4063
sa(dp4064
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00467'
p4065
sg5
S'http://bio2rdf.org/drugbank:DB00277'
p4066
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'THEOPHYLLINE'
p4067
sg27
Nsg28
S'Theophylline-related adverse effects have occurred in patients when theophylline and enoxacin were coadministered.| \r'
p4068
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ENOXACIN'
p4069
sa(dp4070
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p4071
sg5
S'http://bio2rdf.org/drugbank:DB00277'
p4072
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'THEOPHYLLINE'
p4073
sg27
Nsg28
S'In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.| \r'
p4074
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERYTHROMYCIN'
p4075
sa(dp4076
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p4077
sg5
S'http://bio2rdf.org/drugbank:DB00277'
p4078
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'THEOPHYLLINE'
p4079
sg27
Nsg28
S'Therefore, if theophylline is co-administered with fluvoxamine maleate, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of theophylline should to monitored.| \r'
p4080
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p4081
sa(dp4082
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00448'
p4083
sg5
S'http://bio2rdf.org/drugbank:DB00277'
p4084
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'THEOPHYLLINE'
p4085
sg27
Nsg28
S'Nonetheless, individual patients may require additional titration of their theophylline dosage when lansoprazole is started or stopped to ensure clinically effective blood levels.| \r'
p4086
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Lansoprazole'
p4087
sa(dp4088
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00008'
p4089
sg5
S'http://bio2rdf.org/drugbank:DB00277'
p4090
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'THEOPHYLLINE'
p4091
sg27
Nsg28
S'Theophylline serum levels should be monitored and appropriate dose adjustments considered for patients given both theophylline and PEGASYS.| \r'
p4092
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Pegasys'
p4093
sa(dp4094
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p4095
sg5
S'http://bio2rdf.org/drugbank:DB00277'
p4096
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'THEOPHYLLINE'
p4097
sg27
Nsg28
S'Theophylline Grepafloxacin is a competitive inhibitor of the metabolism of theophylline.| \r'
p4098
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p4099
sa(dp4100
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00654'
p4101
sg5
S'http://bio2rdf.org/drugbank:DB02731'
p4102
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'THIMEROSAL'
p4103
sg27
Nsg28
S'In vitro studies have shown that precipitation occurs when eye drops containing thimerosal are mixed with latanoprost.| \r'
p4104
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LATANOPROST'
p4105
sa(dp4106
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p4107
sg5
S'http://bio2rdf.org/drugbank:DB00906'
p4108
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TIAGABINE'
p4109
sg27
Nsg28
S'Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.| \r'
p4110
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CARBAMAZEPINE'
p4111
sa(dp4112
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p4113
sg5
S'http://bio2rdf.org/drugbank:DB00906'
p4114
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TIAGABINE'
p4115
sg27
Nsg28
S'Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.| \r'
p4116
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p4117
sa(dp4118
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p4119
sg5
S'http://bio2rdf.org/drugbank:DB00906'
p4120
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TIAGABINE'
p4121
sg27
Nsg28
S'Phenytoin: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing AEDs.| \r'
p4122
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p4123
sa(dp4124
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00794'
p4125
sg5
S'http://bio2rdf.org/drugbank:DB00906'
p4126
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TIAGABINE'
p4127
sg27
Nsg28
S'Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.| \r'
p4128
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PRIMIDONE'
p4129
sa(dp4130
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p4131
sg5
S'http://bio2rdf.org/drugbank:DB00906'
p4132
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TIAGABINE'
p4133
sg27
Nsg28
S'Valproate: Tiagabine causes a slight decrease (about 10%) in steady-state valproate concentrations.| \r'
p4134
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Valproate'
p4135
sa(dp4136
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p4137
sg5
S'http://bio2rdf.org/drugbank:DB00204'
p4138
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Tikosyn'
p4139
sg27
Nsg28
S'If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.| \r'
p4140
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIMETIDINE'
p4141
sa(dp4142
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p4143
sg5
S'http://bio2rdf.org/drugbank:DB00204'
p4144
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Tikosyn'
p4145
sg27
Nsg28
S'Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.| \r'
p4146
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p4147
sa(dp4148
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01018'
p4149
sg5
S'http://bio2rdf.org/drugbank:DB00373'
p4150
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TIMOLOL'
p4151
sg27
Nsg28
S'Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.| \r'
p4152
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GUANFACINE'
p4153
sa(dp4154
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00636'
p4155
sg5
S'http://bio2rdf.org/drugbank:DB01124'
p4156
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TOLBUTAMIDE'
p4157
sg27
Nsg28
S'The hypoglycemic effect of tolbutamide has been reported to increase when Atromid-S is given concurrently.| \r'
p4158
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Atromid-S'
p4159
sa(dp4160
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00036'
p4161
sg5
S'http://bio2rdf.org/drugbank:DB00302'
p4162
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TRANEXAMIC ACID'
p4163
sg27
Nsg28
S'Although the specific drug interaction was not studied in a clinical trial, there have been more than 50 episodes of concomitant use of antifibrinolytic therapies (i.e., tranexamic acid, aminocaproic acid) and NovoSeven.| \r'
p4164
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NovoSeven'
p4165
sa(dp4166
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00951'
p4167
sg5
S'http://bio2rdf.org/drugbank:DB00609'
p4168
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Trecator'
p4169
sg27
Nsg28
S'Trecator has been found to temporarily raise serum concentrations of isoniazid.| \r'
p4170
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ISONIAZID'
p4171
sa(dp4172
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p4173
sg5
S'http://bio2rdf.org/drugbank:DB00384'
p4174
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TRIAMTERENE'
p4175
sg27
Nsg28
S'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.| \r'
p4176
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOFETILIDE'
p4177
sa(dp4178
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00999'
p4179
sg5
S'http://bio2rdf.org/drugbank:DB00384'
p4180
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TRIAMTERENE'
p4181
sg27
Nsg28
S'Coadministration of triamterene and hydrochlorothiazide capsules resulted in a higher plasma amantadine concentration in a 61 year old man receiving amantadine (amantadine hydrochloride) 100 mg TID for Parkinsons disease.1 It is not known which of the components of triamterene and hydrochlorothiazide capsules contributed to the observation or if related drugs produce a similar response.| \r'
p4182
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HYDROCHLOROTHIAZIDE'
p4183
sa(dp4184
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p4185
sg5
S'http://bio2rdf.org/drugbank:DB00897'
p4186
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TRIAZOLAM'
p4187
sg27
Nsg28
S'The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.| \r'
p4188
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DILTIAZEM'
p4189
sa(dp4190
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p4191
sg5
S'http://bio2rdf.org/drugbank:DB00897'
p4192
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TRIAZOLAM'
p4193
sg27
Nsg28
S'Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| \r'
p4194
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p4195
sa(dp4196
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p4197
sg5
S'http://bio2rdf.org/drugbank:DB00897'
p4198
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TRIAZOLAM'
p4199
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p4200
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR MESYLATE'
p4201
sa(dp4202
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p4203
sg5
S'http://bio2rdf.org/drugbank:DB00897'
p4204
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TRIAZOLAM'
p4205
sg27
Nsg28
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p4206
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SAQUINAVIR'
p4207
sa(dp4208
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00897'
p4209
sg5
S'http://bio2rdf.org/drugbank:DB00897'
p4210
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TRIAZOLAM'
p4211
sg27
Nsg28
S'Triazolam Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.| \r'
p4212
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TRIAZOLAM'
p4213
sa(dp4214
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01015'
p4215
sg5
S'http://bio2rdf.org/drugbank:DB00440'
p4216
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TRIMETHOPRIM'
p4217
sg27
Nsg28
S'Trimethoprim Alone or in Combination with Sulfamethoxazole: Concomitant use of trimethoprim alone or in combination with sulfamethoxazole is contraindicated.| \r'
p4218
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SULFAMETHOXAZOLE'
p4219
sa(dp4220
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p4221
sg5
S'http://bio2rdf.org/drugbank:DB01361'
p4222
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TROLEANDOMYCIN'
p4223
sg27
Nsg28
S'Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| \r'
p4224
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p4225
sa(dp4226
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00514'
p4227
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p4228
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'VALDECOXIB'
p4229
sg27
Nsg28
S'Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.| \r'
p4230
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DEXTROMETHORPHAN'
p4231
sa(dp4232
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p4233
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p4234
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'VALDECOXIB'
p4235
sg27
Nsg28
S'Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.| \r'
p4236
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p4237
sa(dp4238
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01016'
p4239
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p4240
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'VALDECOXIB'
p4241
sg27
Nsg28
S'Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.| \r'
p4242
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GLYBURIDE'
p4243
sa(dp4244
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p4245
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p4246
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'VALDECOXIB'
p4247
sg27
Nsg28
S'Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.| \r'
p4248
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p4249
sa(dp4250
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00514'
p4251
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p4252
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'VALDECOXIB'
p4253
sg27
Nsg28
S'Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.| \r'
p4254
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENARSAZINE CHLORIDE'
p4255
sa(dp4256
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p4257
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p4258
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'VALDECOXIB'
p4259
sg27
Nsg28
S'Anticonvulsants (Phenytoin): Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).| Patients already stabilized on valdecoxib should be closely monitored for loss of symptom control with phenytoin coadministration.| \r'
p4260
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYTOIN'
p4261
sa(dp4262
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00951'
p4263
sg5
S'http://bio2rdf.org/drugbank:DB00313'
p4264
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Valproate'
p4265
sg27
Nsg28
S'Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid.| \r'
p4266
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ISONIAZID'
p4267
sa(dp4268
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p4269
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p4270
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Verapamil'
p4271
sg27
Nsg28
S'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| \r'
p4272
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p4273
sa(dp4274
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p4275
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p4276
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Verapamil'
p4277
sg27
Nsg28
S'In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.| \r'
p4278
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOFETILIDE'
p4279
sa(dp4280
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00537'
p4281
sg5
S'http://bio2rdf.org/drugbank:DB00900'
p4282
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Videx'
p4283
sg27
Nsg28
S'Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.| \r'
p4284
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIPROFLOXACIN'
p4285
sa(dp4286
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01155'
p4287
sg5
S'http://bio2rdf.org/drugbank:DB00900'
p4288
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Videx'
p4289
sg27
Nsg28
S'Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| \r'
p4290
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Factive'
p4291
sa(dp4292
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01004'
p4293
sg5
S'http://bio2rdf.org/drugbank:DB00900'
p4294
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Videx'
p4295
sg27
Nsg28
S'A 21 (17)% decrease in the steady-state AUC of ganciclovir was observed when VIDEX was administered 2 hours prior to ganciclovir, but not when the two drugs were administered simultaneously (n = 12).| Ganciclovir: Administration of VIDEX 2 hours prior to or concurrent with oral ganciclovir was associated with a 111 (114)% increase in the steady-state AUC of didanosine (n = 12).| \r'
p4296
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GANCICLOVIR'
p4297
sa(dp4298
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01059'
p4299
sg5
S'http://bio2rdf.org/drugbank:DB00900'
p4300
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Videx'
p4301
sg27
Nsg28
S'Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.| \r'
p4302
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NORFLOXACIN'
p4303
sa(dp4304
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00542'
p4305
sg5
S'http://bio2rdf.org/drugbank:DB00533'
p4306
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Vioxx'
p4307
sg27
Nsg28
S'In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.| \r'
p4308
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BENAZEPRIL'
p4309
sa(dp4310
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p4311
sg5
S'http://bio2rdf.org/drugbank:DB00533'
p4312
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Vioxx'
p4313
sg27
Nsg28
S'Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.| \r'
p4314
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM CATION'
p4315
sa(dp4316
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p4317
sg5
S'http://bio2rdf.org/drugbank:DB00533'
p4318
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Vioxx'
p4319
sg27
Nsg28
S'Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.| \r'
p4320
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LITHIUM'
p4321
sa(dp4322
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p4323
sg5
S'http://bio2rdf.org/drugbank:DB00533'
p4324
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Vioxx'
p4325
sg27
Nsg28
S'At higher than recommended doses, VIOXX 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving methotrexate 7.5 to 15 mg/week for rheumatoid arthritis.| Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly.| \r'
p4326
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHOTREXATE'
p4327
sa(dp4328
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p4329
sg5
S'http://bio2rdf.org/drugbank:DB00533'
p4330
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Vioxx'
p4331
sg27
Nsg28
S'Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.| \r'
p4332
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p4333
sa(dp4334
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00479'
p4335
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p4336
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Vistide'
p4337
sg27
Nsg28
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p4338
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMIKACIN'
p4339
sa(dp4340
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00681'
p4341
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p4342
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Vistide'
p4343
sg27
Nsg28
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p4344
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPHOTERICIN B'
p4345
sa(dp4346
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00529'
p4347
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p4348
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Vistide'
p4349
sg27
Nsg28
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p4350
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FOSCARNET'
p4351
sa(dp4352
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00738'
p4353
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p4354
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Vistide'
p4355
sg27
Nsg28
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p4356
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Pentamidin'
p4357
sa(dp4358
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00684'
p4359
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p4360
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Vistide'
p4361
sg27
Nsg28
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p4362
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOBRAMYCIN'
p4363
sa(dp4364
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00512'
p4365
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p4366
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Vistide'
p4367
sg27
Nsg28
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p4368
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VANCOMYCIN'
p4369
sa(dp4370
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00158'
p4371
sg5
S'http://bio2rdf.org/drugbank:DB00115'
p4372
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Vitamin B12'
p4373
sg27
Nsg28
S'Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid.| \r'
p4374
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FOLIC ACID'
p4375
sa(dp4376
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00531'
p4377
sg5
S'http://bio2rdf.org/drugbank:DB01156'
p4378
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Wellbutrin'
p4379
sg27
Nsg28
S'Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).| \r'
p4380
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cyclophosphamide'
p4381
sa(dp4382
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p4383
sg5
S'http://bio2rdf.org/drugbank:DB01156'
p4384
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Wellbutrin'
p4385
sg27
Nsg28
S'Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.| \r'
p4386
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'THEOPHYLLINE'
p4387
sa(dp4388
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p4389
sg5
S'http://bio2rdf.org/drugbank:DB00549'
p4390
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ZAFIRLUKAST'
p4391
sg27
Nsg28
S'Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| \r'
p4392
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tikosyn'
p4393
sa(dp4394
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p4395
sg5
S'http://bio2rdf.org/drugbank:DB00962'
p4396
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ZALEPLON'
p4397
sg27
Nsg28
S'Coadministration of single, oral doses of zaleplon with erythromycin (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in zaleplons maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.| \r'
p4398
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERYTHROMYCIN'
p4399
sa(dp4400
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00575'
p4401
sg5
S'http://bio2rdf.org/drugbank:DB00612'
p4402
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Zebeta'
p4403
sg27
Nsg28
S'In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that ZEBETA be discontinued for several days before the withdrawal of clonidine.| \r'
p4404
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLONIDINE'
p4405
sa(dp4406
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p4407
sg5
S'http://bio2rdf.org/drugbank:DB00612'
p4408
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Zebeta'
p4409
sg27
Nsg28
S'ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.| \r'
p4410
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p4411
sa(dp4412
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p4413
sg5
S'http://bio2rdf.org/drugbank:DB00495'
p4414
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ZIDOVUDINE'
p4415
sg27
Nsg28
S'Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of VISTIDE infusion.| \r'
p4416
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROBENECID'
p4417
sa(dp4418
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00649'
p4419
sg5
S'http://bio2rdf.org/drugbank:DB00495'
p4420
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ZIDOVUDINE'
p4421
sg27
Nsg28
S'Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.| \r'
p4422
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'STAVUDINE'
p4423
sa(dp4424
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00495'
p4425
sg5
S'http://bio2rdf.org/drugbank:DB00495'
p4426
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ZIDOVUDINE'
p4427
sg27
Nsg28
S'Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.| \r'
p4428
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZIDOVUDINE'
p4429
sa.